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1.  Introduction 
 
1.1 Healthcare biotechnology 
Biotechnology has revolutionized the way diseases are treated. 
Recombinant DNA technology has allowed the development of bio-
pharmaceuticals, which can mimic the complex body proteins. These unique 
agents have helped the treatment of diseases in entirely new ways. An 
important of modern pharmacotherapy is based on “biologics” which are the 
biotechnology-derived drugs. The ability to produce biologics has resulted in 
the development of innovative drugs and vaccines for clinical needs, including 
cancers, rheumatoid arthritis, Crohn's disease, multiple sclerosis, macular 
degeneration, retinal vein occlusions and psoriatic skin diseases (1). 
Biological products include a wide range of products such as vaccines, 
blood and blood components, allergenics, somatic cells, gene therapy, tissues, 
and recombinant therapeutic proteins and can be composed of sugars, proteins, 
or nucleic acids or complex combinations of these substances, or may be living 
entities such as cells and tissues. Biologics are originated from human, animal, 
or microorganism and may be produced by biotechnology methods and other 
cutting-edge technologies. Gene-based and cellular biologics, for example, 
often are at the forefront of biomedical research, and may be used to treat a 
variety of medical conditions for which no other treatments are available. 
While many drugs have a known structure and are chemically synthesized, 
most biologics are complex mixtures that are not easily identified or 
characterized. Biological products, including those manufactured by 
biotechnology, tend to be heat sensitive and susceptible to microbial 
contamination. Therefore, it is necessary to use aseptic principles from initial 
manufacturing steps, which is also in contrast to most conventional drugs.  
Biological products often represent the cutting-edge of biomedical 
research and, in time, may offer the most effective means to treat a variety of 
medical illnesses and conditions that presently have no other treatments 
available (2). 
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The academic research groups require recombinant mammalian proteins 
for functional analysis (e.g. cellular signaling pathways) and high resolution 
structure determination and the production of these proteins in recombinant 
systems had a profound impact in many areas such as the biotech sector. As a 
matter of fact, the biotech sector has heavily invested in the production of 
protein therapeutics (i.e. biologics), as a relatively new and transformative 
approach to treating human diseases (3). 
 
1.2 Biotech drug market steadily expands 
Today several biologics such as monoclonal antibodies, insulins, peptide 
hormones and analogues, haematopoietic and non-haematopoietic growth 
factors, interferons, interleukins, erythropoietins, fusion proteins, 
“recombinantly produced antigens” (vaccines) and other innovative products 
that account for a substantial portion of all human medicines have entered into 
the global market of pharmaceuticals. Globally the sale of biologics was 
approximately $150 billion in 2015. Approximately, 30% of the 
pharmaceutical and biotech industries pipeline is composed of biologics, and 
by 2020 ten of 20 top selling drugs will be biologics. Presently biologics, 
including Humira (Adalimumab), Enbrel (Etanercept), Remicade (Infliximab), 
Avastin (Bevacizumab), Lantus (Insulin Glargine), Rituxan (Rituxiamab), 
Herceptin (Trastuzumab), Prolia (Denosumab) and Lucentis (Ranibizumab), 
are among the top selling pharmaceuticals worldwide. They are often 
prescribed long-term for chronic medical conditions, although they are 
expensive yet. For this reason there is a demand for generic cheaper versions 
of these drugs. The generic version of biologics, called “biosimilars” are the 
most required on the market although they cannot be exactly the same as 
innovators owing to structural and manufacturing complexities of 
biopharmaceuticals, making them similar but not exactly same as in the case 
of less complex small molecule pharma drugs (1). 
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1.3 Manufacturing of a biotechnological product: an overview 
Large molecules (e.g., therapeutic proteins) are manufactured by a 
number of methods, including extraction from natural sources (as done in the 
past to extract erythropoietin from urine), modification of naturally occurring 
protein, mammalian cell culture in vivo, production by microorganisms, and 
chemical synthesis.  
Generally, manufacturing recombinant therapeutic proteins involves: 
• Cloning of a specific gene in the laboratory, or the construction of a 
synthetic gene; 
• Insertion into a host cell and subcloning in a microorganism or cell 
culture; 
• Process development on a pilot scale to optimize yield and quality; 
• Large-scale fermentation or cell culture processes; 
• Purification of the macromolecular proteins; 
• Animal testing, clinical testing, regulatory approval, and marketing. 
This applies to both recombinant deoxyribonucleic acid-derived products 
as well as recombinant proteins. 
The manufacturing processes follow similar basic requirements for 
process validation, environmental control, aseptic manufacturing, and quality 
control/quality assurance systems as required for pharmaceutical products, 
though with a great deal more complexity, as the processes of cell propagation, 
purification methods, and analytical controls are significantly different and 
more detailed (4). 
Overall, the first part of manufacturing process is the upstream that refers 
to cell culture, leading to fermentation. Manufacturing starts with cell 
cultivation where an aliquot (a vial containing cell material) is taken from the 
cell bank and incubated on a small scale (shake flask). This is followed by a 
sequence of scale-up steps, which are typically different in volume by a factor 
10, to generate the inoculation culture for the production fermenter. Cells are 
propagated and the target protein generated in the fermentation step. The 
nutrients for cell metabolism are supplied through the medium and aeration. In 
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upstream the major strategic issue is whether the cell culture should be run in 
the batch, fed-batch, or in continuous mode, the latter being very attractive at 
low expression levels because of higher yields in continuous processing. After 
harvesting the cells from the cultivation broth, the supernatant (the aqueous 
water phase) is separated from the cell mass and this can be done by 
centrifugation or filtration. If the product is expressed intracellularly in 
inclusion bodies, the cells have to be disrupted, the cell debris separated and 
the target proteins dissolved in a suitable aqueous solvent. If the target protein 
is denatured, a refolding step may become necessary to restore the three-
dimensional structure and therefore its therapeutic functionality. After 
refolding, the solution contains the correctly folded protein and impurities from 
the preceding process steps. This is comparable to the situation of 
extracellularly expressed proteins after elimination of the biomass. In this latter 
case the product does not reside in the cells, but in the watery supernatant (5). 
The downstream process begins with the “harvest” where the cells are 
separated from the supernatant. The target proteins are separated from host and 
process-related impurities by several purification unit operations. These are 
divided into capture, intermediary purification, and polishing, resulting in the 
purified bulk material (drug substance). The aim of this section is to remove 
impurities similar to the product, such as HCPs, denatured forms of the protein, 
residual DNA or other byproducts. For isolation and concentration of the 
protein of interest (POI) a chromatographic step (direct-capture 
chromatography) and ultrafiltration are used; furthermore, the aqueous buffer 
can be exchanged by diafiltration in order to prepare the solution for the 
subsequent purification steps. Chromatography requires a solid matrix as 
stationary phase. After isolation/concentration, the protein is obtained in 
solution, free of crude impurities. Ultimate purification is done in “polishing” 
phase, where a whole range of chromatographic processes can be applied. The 
end of the process chain is represented by the formulation step for preparing a 
dosage form ready for administration to humans by converting Drug Substance 
(DS) into a Drug Product (DP). The aim of purification is to obtain the 
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dissolved protein as pure as possible and with optimal stability to make long-
term storage at moderate conditions possible (5). 
The entire manufacturing process must be tightly connected at each unit 
of operation of upstream and downstream processing. Yield variation, impurity 
diversity, and potency achieved are the factors that can significantly affect all 
steps (4-5). A scheme of a hypothetical drug substance production process is 
shown in Figure 1. It is interesting to note that the process is designed in order 
to achieve a fully disposable set-up. 
 
1.4 Key factors for the process development of a therapeutic 
recombinant protein 
The key factors for the process development evaluation are related with 
the costs, simplicity, robustness and reproducibility of the manufacturing 
operations. Starting from the upstream phase of a process, a crucial key factor 
is the fermentation titer that is the achievable product concentration in grams 
per liter fermentation volume at the end of the fermentation. The duration of 
the process depends on the cell growth rate, the achievable cell density and the 
productivity of the individual cell. Another key factor in the downstream 
process is related with the overall yield which represents the final product 
content referred to initial volume of the production campaign.  
Type, capacity and time of process steps are the main factors for the 
evaluation and optimization of plant usage. The type and capacity of the 
process steps determine the type of the plant and the process time. 
The capacity of an individual step indicates how often such a step has to 
be performed for the manufacturing of a desired product quantity.  
Robustness of the process is very important because delivers a consistent 
product quality within a wide range of process parameter variations. High 
robustness simplifies process validation and technical process control, 
decreasing the risks of rejects. The specification ranges of the input parameters 
(e.g. stirrer speed, gas flow rate, temperature range, volume, linear flow rate, 
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Figure 1: A biopharmaceutical drug substance production process (6) 
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etc.) are normally established in development studies and should be broad and 
accomplishable with technical equipment.  
All the steps of the process are monitored by analytical approaches 
because it should be clear which and how many tests have to be performed for 
validation, In-Process Control (IPC), release, stability testing and 
environmental monitoring. 
Raw materials are media, buffer preparations, chromatography gels, 
pharmaceutical water and packing material. Raw materials such as media and 
excipients of animal origin are very important in the evaluation and in the risk 
assessment of the manufacturing process but they are difficult to procure due 
to the limited offer of certified Transmissible Spongiform Encephalopathy 
(TSE)/Bovine Spongiform Encephalopathy (BSE)-free material; moreover, 
there is a remaining risk for contamination and high regulatory hurdles for 
approval of processes using these materials. Synthetic media can be used 
although they are too much expensive and may not support the process as well 
as their natural equivalents. Considering chromatography gels, the operation 
of some particular preparative chromatographic columns requires facilities 
suited to handle organic solvents. Finally, the transfer of processes is 
significantly simplified if standard packaging materials are used instead of 
custom-made vials or syringes. 
Product stability means the ability of a product to retain its properties over 
a long period of time under defined environmental conditions. Usually, 
biopharmaceuticals tend to degrade with time and they are sensitive to extreme 
environmental conditions. Product stability has a significant impact on process 
design as well as transport and storage conditions. Poor stability impose a 
quick turnover after the upstream phase and downstream processing and the 
use of cold temperatures of 2–8 °C could be necessary. It is also important to 
consider that virus or protease inactivation steps, that need to apply high 
temperature or pH shifts, can go along with high product losses. Intermediates 
have to be correctly stored and tested for stability. At the end of the supply 
chain, the distribution to the client is associated with risks, since the sensitive 
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drug leaves the area controlled by the manufacturer. This can cause restrictions 
to the marketing profile and consequentially disadvantages compared to 
competitive products (5). The European Commission has published EU 
(European Union) Guidelines on Good Distribution Practice (GDP) in 1994. 
Revised guidelines were published in March 2013 in order to take into account 
recent advances in practices for appropriate storage and distribution of 
medicinal products in the European Union, according to new requirements 
introduced by Directive 2011/62/EU. Moreover a “question and answer” 
document (March 2014) respond to frequently asked questions in relation to 
the guidelines on GDP of medicinal products for human use (7). 
 
1.5 The Good Manufacturing Practices (GMPs) 
The GMPs are defined as “that part of quality assurance which ensure that 
products are consistently produced and controlled to the quality standards 
appropriate to their intended use”. GMPs are guidelines issued and elaborated 
by international organizations and institutions, in collaboration with 
Pharmaceutical Industry and several national regulatory authorities in different 
regions and countries. GMPs are guidelines which govern the production, 
distribution and supply of a drug and they are a necessary condition for 
marketing authorization. They guarantee the highest standards of efficacy, 
quality and safety in any process that involves the manufacture of health 
products (8).  
The European Medicines Agency (EMA) is a decentralized agency of the 
EU. The Agency is responsible for the scientific evaluation of medicinal 
products developed by pharmaceutical companies in the EU. EMA is 
responsible for emphasizing the development of guidelines, setting standards 
and contribution to international cooperation activities with authorities outside 
the EU. Directive 2001/83/EC provides the Community codes for medicinal 
products for human use. On 2004, the Council of the EU and the European 
Parliament decided some amendments (Regulation [EEC] No 2309/93 by 
Regulation [EC] No 726/2004) (9-10). 
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Volume 4 of "The rules governing medicinal products in the European 
Union" contains guidance for the interpretation of the principles and guidelines 
of good manufacturing practices for medicinal products for human and 
veterinary use laid down in Commission Directives 91/356/EEC, as amended 
by Directive 2003/94/EC, and 91/412/EEC respectively. All medicinal 
products are assessed by a competent authority to ensure compliance with 
contemporary requirements of safety, quality and efficacy (11). 
The EU, including the European Commission and the EMA, has 
confidentiality arrangements with the Food and Drug Administration (FDA), 
the agency of the US Department of Health and Human Services, responsible 
for protecting the Public Health by assuring the appropriate regulation of 
medicinal products for human use, and through the encouragement of product 
innovations. The FDA GMPs regulations can be found in Title 21 of the Code 
of Federal Regulations (CFRs) (12). The arrangements allow the exchange of 
confidential information between the EU and the FDA as part of their 
regulatory and scientific processes. This includes information on advance 
drafts of legislation and regulatory guidance documents, as well as non-public 
information related to ensuring the quality, safety and efficacy of medicinal 
products for human and veterinary use.  
A close cooperation between the several national and international entities 
is necessary in order to achieve a regulatory harmonization of GMP for 
medicinal products for human use by the competent authorities. For this reason 
in 1990 the International Conference on Harmonization (ICH) was established, 
with the propose of making recommendations, implementing standards of the 
International Organization for Standardization (ISO) and employing 
harmonization in the guidelines and technical requirements for registration of 
pharmaceutical products. This organization is very important because brings 
together the drug regulatory authorities and the pharmaceutical industry in 
Europe, Japan and the United States (13). 
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1.5.1 The process development of a biotechnological product 
meets the Good Manufacturing Practices (GMPs) 
1.5.1.1 Cell lines and expression systems 
The starting material for manufacturing therapeutic proteins are the 
bacterial, yeast, insect, or mammalian cell culture that expresses the protein 
product or monoclonal antibody of interest. The cell seed lot, that consists of 
aliquots of a single culture, are used by manufacturers to ensure identity and 
purity of the starting raw material. The Master Cell Bank (MCB) is derived 
from a single colony (bacteria, yeast) or a single eukaryotic cell, stored 
cryogenically to ensure genetic stability. The Working Cell Bank (WCB) is the 
quantity of cells derived from one or more ampoules of the MCB used to 
initiate the production batch (Figure 2) (4). The MCB and the WCB should be 
tested and properly characterized in accordance with the prescribed 
International Conference on Harmonization (ICH) Q5D protocol (14). 
The tests that are generally performed for rigorously test the identity of 
the MCB are genotypic characterization by DNA fingerprinting, phenotypic 
characterization by nutrient requirements, isoenzyme analysis, growth and 
morphological characteristics, reproducible production of desired product, 
molecular characterization of vector/cloned fragment by restriction enzyme 
mapping, sequence analysis, assays to detect viral contamination, reverse 
transcriptase assay to detect retroviruses, sterility test and mycoplasma test to 
detect other microbial contaminants (4). 
For WCB, a reduced level of characterization is required. The tests that 
are generally performed are the phenotypic characterization, restriction 
enzyme mapping, sterility and mycoplasma testing and the reproducible 
production of the desired product (4). Seed lots and cell banks should be stored 
and used in such a way as to minimize the risks of contamination, (e.g. stored 
in the vapor phase of liquid nitrogen in sealed containers) or alteration and 
control measures should be implemented to prevent mix-up and cross 
contaminations (15). 
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Figure 2: When a cell line is to be used over many manufacturing cycles, a cell banking 
system consisting of a master cell bank (MCB) and a working cell bank (WCB) is 
recommended. Cells from the MCB are expanded to form the WCB, which is 
characterized for cell viability prior to use in the manufacturing process (16) 
 
The choice of expression system depends on factors such as type of target 
protein, post-translational modifications, expression level, intellectual 
property rights, and economy of manufacture. Information about the 
construction of the expression vector, the fragment containing the genetic 
material that encodes the desired product, and the relevant genotype and 
phenotype of the host cell(s) are submitted as part of a product application (4). 
 
1.5.1.2 Media and buffers 
In fermentation the cells are incubated in the nutrient medium, an aqueous 
solution that contains the nutrients important for cell growth and metabolism. 
In a process development the medium should support the vital functions and 
the cellular reactivity of the target cell and should be composed in such a way 
that purification is not unnecessarily complicated. It should not interfere with 
the analytical methods used in the process and should not interact with the 
segregated target protein or other segregated proteins (5). 
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Most mammalian cell cultures require animal fetal serum for growth. 
Serum should be sterile, although sometimes could be a source of 
contamination by adventitious organisms like mycoplasma. Serum could also 
be contaminated with BSE agent, therefore it’s important to know the source 
of the serum and require certification that the serum does not come from areas 
where BSE is endemic as matter of fact that there is no sensitive in vitro assay 
to detect the presence of this agent. Other potential sources of BSE may be 
proteases and other enzymes derived from bovine sources (4). The risk of 
contamination of starting and raw materials during their passage along the 
supply chain must be assessed, with particular emphasis on TSE (14-15). 
Biological product manufacturers have been requested to determine the 
origin of these materials used in manufacturing. The media used must be 
sterilized generally by Sterilizing In Place (SIP) or by using a Continuous 
Sterilizing System (CSS) process. Any nutrients or chemicals added beyond 
this point must be sterile (4).  
Annex 2 of the volume 4 of EU guidelines regulates the characteristics of 
medium for the production of a biotechnology product. In particular, since 
media and reagents are designed to promote the growth of cells or microbial 
organisms, typically in an axenic state, it is necessary to control and prevent 
the unwanted bioburden and associated metabolites and endotoxins. The 
source, origin and suitability of biological starting and raw materials (e.g. 
cryoprotectants, feeder cells, reagents, culture media, buffers, serum, enzymes, 
cytokines and growth factors) should be clearly defined. Where the necessary 
tests take a long time, it may be permissible to process starting materials before 
the results of the tests are available, the risk of using a potentially failed 
material and its potential impact on other batches should be clearly understood 
and assessed. In such cases, release of a finished product is conditional on 
satisfactory results of these tests. The identification of all starting materials 
should be in compliance with the requirements appropriate to its stage of 
manufacture. 
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The growth promoting properties of culture media should be 
demonstrated to be suitable for its intended use. If possible, media should be 
sterilized in situ. In-line sterilizing filters, for routine addition of gases, media, 
acids or alkalis, anti-foaming agents etc. to fermenters, should be used where 
possible. The level and type of micro-organism present in raw materials, 
media, biological substances, buffers, intermediates or products must be 
measured by bioburden analysis.  
Starting and raw materials may need additional documentation on the 
source, origin, distribution chain, method of manufacture, and controls applied, 
to assure an appropriate level of control including their microbiological quality 
(14-15). 
 
1.5.1.3 Culture growth (upstream manufacturing) 
Upstream manufacturing include operations for cell expansion and culture 
growth, starting with a single vial of frozen cells and reaching the large-scale 
terminal reactor where the targeted protein is expressed. These operations 
require highly skilled specialists trained in microbiological processes, GMPs, 
fermenter and bioreactor systems, automation systems, and in-process analysis 
instruments (17).  
Cell cultures are run in batch, fed-batch, or continuous mode depending 
on expression system used and process development results. Bioreactor 
inoculation, transfer, and harvesting operations must be done using validated 
aseptic techniques and additions or withdrawals from industrial bioreactors are 
generally done through steam sterilized lines, steam-lock assemblies or 
disposable sterile ports. It is important for a bioreactor system to be closely 
monitored and tightly controlled to achieve the proper and efficient expression 
of the desired product. Growth rate, pH, waste by-product level, viscosity, 
addition of chemicals, density, mixing, aeration, and foaming are the 
parameters for the fermentation process and these must be specified and 
monitored. Other factors that can affect the finished product are shear forces, 
process-generated heat, and effectiveness of seals and gaskets (4). 
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There are two main types of bioreactors: multiple-use (stainless steel) or 
single-use bioreactors (disposable). The first one is the most important and the 
predominant version of bioreactor. It generally requires a large capital 
investment for purchase and installation and also validated processes for 
cleaning, and sterilization. For this reason single-use bioreactors are being used 
increasingly.  
Disposable bioreactors utilize a disposable sterilized cell chamber in 
which the cell culture is maintained and where the risk of cross-contamination 
is minimized. The use of disposable bioreactors decreases the amount of 
validation, cleaning, sterilization, and maintenance needed per bioreactor run. 
For this reason, disposable bioreactors runs are able to be scheduled closer 
together allowing for an increase in plant production (Figure 3). 
a)                                                                              b)                                                         
 
Figure 3: Disposable bioreactors: a) Rocking motion bioreactors are mechanically-
driven reactor systems able to produce a “wave” inside a disposable plastic bag in order 
to provide mixing and gas transfer for cell growth. b) Disposable stirred tank 
bioreactor. These bioreactors have single-use mixing systems, and disposable bag 
assemblies for GMP biomanufacturing (18)  
 
The addition of materials or cultures to fermenters and other vessels and 
sampling should be carried out with closed systems or under carefully 
controlled conditions to prevent contamination as described in ICH Q5D 
guidelines and in the operating principles chapter of the annex 2 of the volume 
4 EU GMP guidelines. Moreover these documents underline the importance of 
continuous monitoring some production processes (e.g. in fermentation pH, 
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temperature, agitation rates, pressure cell growth, viability and productivity) 
and these data should form part of the documentation used to control the 
production process (batch record). All the containers, tubes and cell culture 
equipment, if not disposable, must be cleaned, sanitized and sterilized. The 
directive underline the necessity of appropriate in place procedures to detect 
contamination and determine the course of action to be taken. This should 
include procedures to determine the impact of the contamination on the product 
and those to decontaminate the equipment. Foreign organisms observed during 
fermentation processes should be identified as appropriate and the effect of 
their presence on product quality should be assessed, if necessary and the 
results of such assessments should be taken into consideration in the 
disposition of the material produced. Computer programs used to control the 
course of fermentation, data logging, and data reduction and analysis should 
be validated in accordance with 21 CFR part 11 (14-15). 
 
1.5.1.4 Downstream bioprocessing 
Downstream bioprocessing refers to the separation, purification, and 
modification of macromolecules from complex biological feedstocks. The 
feedstock is a cell suspension containing host cells that synthesizes the 
macromolecule of interest. A downstream unit operation, a single step in the 
downstream process, can be categorized into a mechanical separation, 
chemical separation, or dual mechanical/chemical separation step. The 
molecule of interest is separated from the remaining impurities mechanically, 
by its dimensional (size, shape) characteristics, or chemically, by its 
biochemical (electrical charge, interaction with other macromolecules, 
oiliness) properties. Several downstream processing techniques apply both 
mechanical and chemical separations simultaneously, and can be highly 
selective for the molecule of interest. Product separation and purification is 
accomplished through a series of process steps including filtration, 
chromatography, precipitation, and centrifugation. In addition to the separation 
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and purification of the target drug molecule, downstream processes modify the 
drug molecule and its environment.  
 
1.5.1.4.1 Clarification 
Downstream processing begins with the separation of large insoluble 
contaminants from the feedstock or “harvest” solution, usually whole cells and 
cell debris. This mechanical separation process is called clarification. For 
expression systems in which the molecule of interest is secreted outside the 
cell, into the surrounding solution, and a relatively low density of cell debris is 
present, depth filtration is a common clarification technique. Depth filtration 
is a key purification unit operation and often the final step in particle 
conditioning processes involving precipitation and/or flocculation (17).  
The 3D matrix of depth filters is commonly employed for clarification of 
cellular debris, HCPs and DNA, or for capture of solid product and are widely 
used because of low equipment cost and easy scalability from bench scale to 
production phase (Figure 4). Although often used for steric retention, the 
adsorptive properties of certain filters offer the potential for targeted removal 
of impurities at any location in a purification process and have utility as 
polishing steps (19). Several varieties of depth filters are readily available with 
some acting as both mechanical and chemical separators that bind charged 
contaminants from the host cell such as DNA and proteins.  
                                                                                     
 
 
Figure 4: Internal structure of a depth filter. Due to the channel-like nature of the 
filtration medium, the particles are retained throughout the medium within its structure 
(20) 
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Another way to remove large particulate from the feedstock is 
centrifugation. Continuous flow centrifuges are better than traditional 
laboratory centrifuges because they allow the separation of the product from 
the feedstock in a single batch, taking advantage of density differences 
between liquids and solids. After this step the harvest solution is passed 
through different fine filters, in order to protect further downstream processing 
steps from unwanted contaminants and debris (19). It is important that 
harvesting steps are performed using equipment and areas designed to 
minimize the risk of contamination according to rules governing medicinal 
products in the EU and ICH guidelines. Harvest is defined as the procedure to 
remove or inactivate the producing organism, cellular debris and media 
components and must not degrade, contaminate or reduce the quality of the 
molecule of interest. Moreover, the clarification step should be adequate to 
ensure that the intermediate or Active Pharmaceutical Ingredient (API) is 
recovered with consistent quality (21-22). 
 
1.5.1.4.2 Chromatography 
Chromatography is the primary tool used in downstream processing and 
it refers to the separation of molecules that exist together in a solution. Column 
chromatography is the most common form of chromatography in 
biomanufacturing, in which a liquid mobile phase containing the molecule of 
interest passes through a solid stationary phase. The stationary phase, 
commonly referred to as chromatography resin or media, contains immobilized 
chemicals called ligands and can operate in different ways depending on the 
downstream process operation. The different affinity mechanisms have lead to 
the development of different chromatography principles described in Table I. 
The ligands can bind to the product molecule, allowing other unwanted 
molecules to pass through the column and be discarded. This strategy is 
referred to as “bind and elute mode” chromatography. The opposite occurs in 
“flow through” chromatography, in which the molecule of interest passes 
through the column while impurities bind to the ligands.  
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Table I: Chromatographic techniques (5) 
CHROMATOGRAPHIC 
TECHNIQUE 
DESCRIPTION 
Ion exchange 
chromatography (IEX) 
IEX works on basis of the different electrostatically charged 
molecular moieties in a protein. They are capable of binding to 
oppositely charged molecules that are immobilized on the solid 
gel particles in IEX. CEX (negatively charged immobilized 
ions) and AEX (positively charged immobilized ions) depend 
on the polarity of the bound proteins. 
Affinity 
chromatography 
In affinity chromatography, binding to the molecules is 
achieved by a very specific complementary structure between 
ligand and protein. 
Size exclusion 
chromatography (SEC) 
In SEC, the separation principle is based on the pores in the 
particles. When passing the particles, small molecules diffuse 
easier and deeper into the pores than big ones. Consequentially 
the small molecules lose speed relative to the large ones and 
arrive at the column outlet later.  
Hydrophobic interaction 
chromatography (HIC) 
Sample molecules containing hydrophobic and hydrophilic 
regions are applied to an HIC column in a high-salt buffer. The 
salt in the buffer reduces the solvation of sample solutes. As 
solvation decreases, hydrophobic regions that become exposed 
are adsorbed by the hydrophobic media. The more hydrophobic 
the molecule, the less salt is needed to promote binding. 
Usually a decreasing salt gradient is used to elute samples from 
the column in order of increasing hydrophobicity. Sample 
elution may also be assisted by the addition of mild organic 
modifiers or detergents to the elution buffer. 
(Reverse phase 
chromatography) RPC 
RPC separates molecules according to differences in their 
hydrophobicity. In theory, HIC and RPC are closely related 
techniques since both are based upon interactions between 
hydrophobic patches on the surface of biomolecules and the 
hydrophobic surfaces of a chromatography medium. The 
surface of an RPC medium is usually more hydrophobic than 
that of a HIC medium. This leads to stronger interactions that, 
for successful elution, must be reversed using non-polar, 
organic solvents such as acetonitrile or methanol. 
Mixed mode 
chromatography (MMC) 
Mixed-mode chromatography materials contain ligands of 
multimodal functionality that allow protein adsorption by a 
combination of ionic interactions, hydrogen bonds, and/or 
hydrophobic interactions. 
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Many commercially resins, sharing the same ligands, differ from each 
other in polymer that holds the ligands that, normally, does not interact with 
macromolecules in solution. The polymer backbone is a highly porous 
spherical bead in column chromatography, or in a 3D matrix in the case of 
membrane chromatography. The capture chromatography step is the first 
chromatography step of a downstream process and is necessary in order to bind 
the molecule of interest. Capture chromatography usually involves the use of 
an affinity ligand, a molecule that strongly attracts the product macromolecule. 
A common affinity ligand is Protein A, a 42 kDa surface protein found in the 
cell wall of Staphylococcus aureus, that binds human antibodies. Protein A-
based resins are widely used in biomanufacturing to separate monoclonal 
antibody products from mammalian host-cell impurities. For recombinant 
proteins most chromatography resins can be used as the initial capture step 
such as cationic, anionic and mixed mode exchangers. Another 
chromatographic step is the polishing that is able to increase the purity of the 
target macromolecule reducing the amount of contaminant such as HCPs and 
DNA for delivery of the drug to the patient (17).  
Membrane chromatography is an alternative to traditional column 
chromatography, as ligands are attached to a 3D matrix rather than a spherical 
bead. Membrane adsorbers technology is available for some time and recently 
it was used into industrial processes, although only in the Anion Exchange 
Chromatography (AEX), mostly quaternary amine “Q” chemistry. There have 
been publications on the use of Hydrophobic Interaction Chromatography 
(HIC) membrane chromatography to mediate a precipitation purification, 
which has the added innovation of combining the particulate-retaining 
capability of the filter. Another possibility is the use of Cation Exchange 
Chromatography (CEX) membranes. This is predominantly used as a column 
chromatography step in binding and elution mode for the removal of trace 
impurities, predominantly aggregates. The use of membrane chromatography 
(Figure 5) is advantageous for some downstream processes since higher flow 
rates through the chromatography matrix can be achieved as compared to most 
 24 
 
traditional resin types, and capital costs are lower without the need for 
expensive column hardware. However, membrane chromatography can be  not 
convenient to use at commercial production scales, where the material costs of 
the membranes can exceed the cost of column chromatography. A small subset 
of membrane chromatography systems combines the flow rate advantages of 
membrane chromatography with the reusability of traditional column 
chromatography (23). 
 
Figure 5: A significant functional advantage of membranes over resins is that the 
transport of molecules to their binding sites takes place mainly by convection with 
minimal pore diffusion, which results in a binding capacity more or less independent 
of the flow rate (24) 
 
In a downstream processing operation, selecting the right mobile phase is 
equally important as choosing the proper stationary phase. The salt solutions 
that pass through chromatography media that establish the proper mobile phase 
conditions are called buffers. A great deal of attention is directed at buffer 
preparation to ensure that the chemical components meet rigorous regulatory 
standards for pharmaceutical use and the buffers are prepared correctly. 
Advances in disposable technology are particularly applicable to the buffer 
preparation process. A cost to store large volumes of buffer solutions in 
stainless steel tanks is not feasible for most biomanufacturers, so disposable 
plastic bags are preferred (17).  
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The purification procedures that remove contaminants should reduce 
degradation, contamination, and loss of quality of the product of interest. In a 
GMP facility all equipment should be properly cleaned and, as appropriate, 
sanitized after use. Multiple successive batching without cleaning can be used 
if intermediate or API quality is not compromised. When open systems are 
used, purification should be performed under environmental conditions 
appropriate for the preservation of product quality. Additional controls, such 
as the use of dedicated chromatography resins or additional testing, may be 
appropriate if equipment is to be used for multiple products (21-22). 
 
1.5.1.4.3 Tangential Flow Filtration (TFF) 
TFF is a rapid and efficient method for separation and purification of 
biomolecules. It can be applied to a wide range of biological fields such as 
immunology, protein chemistry, molecular biology, biochemistry, and 
microbiology. TFF can be used to concentrate and desalt sample solutions 
ranging in volume from 10 mL to thousands of liters. It can be used to 
fractionate large from small biomolecules (diafiltration), harvest cell 
suspensions, and clarify fermentation broths and cell lysates. 
The pores in a tangential flow filter are small enough that the drug product 
does not pass through and continues flow parallel to the filter surface. Sample 
solution flows through the feed channel and tangent to the surface of the 
membrane as well as through the membrane. The crossflow prevents build up 
of molecules at the surface that can cause fouling. Impurities, salts, and water 
pass through the filter and are discarded. TFF can be utilized as a preparative 
step between chromatography steps or to formulate the product of interest with 
the optimal salts and excipients (25).  
 
1.5.1.4.4 Viral clearance  
Several mammalian expression systems contain viruses that are 
intentionally present to manufacture the drug macromolecule. Foreign viruses 
can also contaminate the cell culture and can be difficult to detect. To protect 
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patients from harmful viral agents, downstream processes have a shield to 
eliminate viral contamination, known as “viral clearance”. The primary viral 
clearance operation in most downstream processes is known as viral filtration. 
Many types of specialized viral filters are available which allow the product 
molecule to pass through but trap viruses. The challenge with viral filtration is 
that some viruses, especially parvoviruses, are very small and similar in size 
to product molecules therefore the precision to which these filters are made is 
critical for patient safety. To ensure the filter performs properly, an air test is 
performed to detect microscopic leaks that could have allowed a virus through. 
Viruses are often susceptible to extreme pH, temperature and detergents, while 
many biologic drugs are not as sensitive. Acid treatment is a common strategy 
for viral reduction in a monoclonal antibody downstream process, while 
detergent treatment is sometimes used to reduce viral contamination for 
enzyme products (15).  
The volume 4 of GMP guidelines refers to ICH Guideline Q5A for 
specific information on viral safety evaluation of biotechnology products 
derived from cell lines. In particular, in the first part, this document describes 
the potential sources of viruses contamination that could occur in MCB or 
adventitious viruses that could be introduced during production. The second 
part describes the testing for viruses for cell line qualification and unprocessed 
bulk while the last part is dedicated to the evaluation and characterization of 
viral clearance procedure. Viral removal and viral inactivation steps are 
defined as critical steps for some processes and should be performed within 
their validated parameters. Appropriate precautions should be taken to prevent 
potential viral contamination from pre-viral to post-viral removal/inactivation 
steps. Therefore, open processing should be performed in areas that are 
separate from other processing activities and have separate air handling units. 
The same equipment is not normally used for different purification steps. 
However, if the same equipment is to be used, it should be appropriately 
cleaned and sanitized before reuse. Appropriate precautions should be taken to 
prevent potential virus carry-over (e.g. through equipment or environment) 
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from previous steps. In order to validate the viral clearance step a scale down 
should be demonstrated. The level of purification of the scaled-down version 
should represent as closely as possible the production procedure. For 
chromatographic equipment, column bed-height, linear flow-rate, flow-rate-
to-bed-volume ratio (i.e., contact time), buffer and gel types, pH, temperature, 
and concentration of protein, salt, and product should be shown to be 
representative of commercial-scale manufacturing. Deviations which cannot 
be avoided should be discussed with regard to their influence on the results 
(26).  
 
1.6 Quality by Design (QbD) and the design space 
QbD is receiving a lot of attention in both the traditional pharmaceutical 
and biopharmaceutical industries subsequent to the FDA published “Guidance 
for Industry: Q8 Pharmaceutical Development” in May 2006 (27). Primary 
challenges in successfully implementing QbD are requirements of a complete 
understanding of the product and the process. This knowledge must include 
understanding the variability in raw materials, the relationship between the 
process and the Critical Quality Attributes (CQAs) of the product, and finally 
relationship between the CQA and the clinical properties of the product (28).  
A good definition of QbD can be found in ICH Q8 (R2): “Quality by 
Design (QbD) is a systematic approach to pharmaceutical development that 
begins with predefined objectives and emphasizes product and process 
understanding and process control, based on sound science and quality risk 
management”. It means designing and developing formulations and 
manufacturing processes to ensure a predefined quality. QbD requires an 
understanding how formulation and process variables influence product 
quality (29-30).  
A systematic approach to pharmaceutical development should start with 
the desired clinical performance and then move to product design. The desired 
product attributes should then drive the process design, and the process design 
should drive the strategies to ensure process performance. This systematic 
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approach may be iterative and thus the circular design as shown in Figure 6. 
The inner circle interacts with many other specific measures of pharmaceutical 
manufacturing, such as specifications and critical process parameters. This 
QbD circle can be divided into two major semicircles, product knowledge and 
process understanding. A critical tool for enabling QbD manufacturing is a 
defined way of linking these two semicircles. These can be connected using 
the concept of a design space described in ICH Q8. A design space is the 
multidimensional combination and interaction of input variables and process 
parameters that have been demonstrated to provide assurance of quality (28). 
Figure 6: QbD systematic approach (28) 
 
1.7 The Design of Experiments (DoE) in the downstream 
process development 
Downstream bioprocessing for biotechnology products may afford more 
immediate opportunities for generation of large design spaces. The use of a 
design space approach is compared to more traditional process limits. In the 
simplest traditional approach to optimize experiments, one parameter is varied 
while all others are fixed. It can wrongly be assumed that the optimum levels 
for the factors analyzed can simply be found by using the optimum levels of 
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the factors obtained in the two series of experiments. Further, the traditional 
set-up does not take into account the parameters interactions where 
experimental factors can be dependent of each other. As follows, with the one-
factor-at-a-time experimental set-up, there is a great risk that the true optimum 
for the studied process is not identified (31). 
DoE is a technique for planning experiments and analyzing the 
information obtained. The technique allows to use a minimum number of 
experiments, in which several experimental parameters are varied 
simultaneously to obtain sufficient information on the effect of each 
individually parameter as well as combined. Based on the obtained data, a 
mathematical model of the studied process is created. The model can be used 
to understand the influence of the experimental parameters on the outcome and 
to find an optimum for the process. The design can be visualized by a cube that 
represents the experimental space to be explored and where factors are 
represented by the axes of the cube (x1, x2, and x3 represent three different 
factors, e.g., pH, conductivity, and temperature). Using DoE, multiple factors 
handled in a single series of experiments can be viewed in arrangements called 
hypercubes as the set-up becomes multidimensional and, depending on the 
study to be performed, different types of designs are available (32).  
 
1.8 How to set-up a DoE 
In order to start a DoE set-up, some basic information regarding the 
process to be studied must be available, for example which factors could 
possibly impact the process. Hence is necessary to define the overall project 
goals and the study objective, define process requirements (measurable) or 
issues that are not strictly part of the DoE, define the size of the study, identify 
all parameters that have an effect on the end result and exclude irrelevant ones, 
pool all available information about the factors and responses, define factors 
and their levels. 
The starting point for any DoE work is to state the objective, define the 
questions about the process to be answered, and choose the relevant factors 
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and ranges. For example in a screening study, the objective could be to identify 
key parameters that impact purity and yield in an affinity chromatography 
capture step. Another objective could be to identify the most suitable 
chromatography medium for achieving high target protein homogeneity in a 
capture or polishing step. These screening studies could subsequently be 
followed by optimization studies, again using DoE, with objectives such as 
maximizing purity and yield. 
Screening DoE explores the effects of a large number of factors in order 
to identify the ones that have significant effect on the response of a process or 
system and to determine which factors need to be further characterized or 
optimized. DoE is typically used for screening studies, optimization studies, 
and robustness testing. Screening explores the effects of a large number of 
factors in order to identify the ones that have significant effect on the response 
of a process or system and to determine which factors need to be further 
characterized or optimized. All critically important variables are considered 
before reducing number of variables while optimization is used for 
determination of optimal factor settings for a process or a system. Robustness 
testing is used for determination of process robustness through the 
identification of the responses that do not vary significantly when the factor 
levels are changed. 
Factors are the input parameters or conditions that have to be controlled 
and varied for a process and should have an impact on the response to measure. 
Quantitative factors are characterized by being on a continuous scale, for 
example, pH, flow rate, and conductivity. Qualitative factors are discrete 
(discontinuous), for example, column type, type of chromatography medium, 
and buffer substance. Uncontrollable factors might affect the response but are 
difficult to manage, for example, ambient temperature or target protein amount 
in the cell culture.  
The second step of DoE set-up define what to measure as responses from 
the process, set the specification limits and define a reliable measurement 
methodology and perform a measurement system analysis. 
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In screening studies, the range should be large enough to increase the 
possibility of covering the optimum and to obtain effects above the noise. In 
optimization DoE, the range should, and can usually be reduced as there is 
more information available at this stage.  
The third step of the DoE approach is the creation of an experimental 
design. This is a process performed by defining factors, factor ranges, and the 
objective. The experimental design is completed by a model, a mathematical 
description of the process, which depends on the complexity of the selected 
design. Terms used in modeling, are the main (linear), interaction (two-factor), 
and quadratic terms. 
Screening designs are useful when the main effects must be determined 
or when we wish to disregard parameter interactions or nonlinear relationships. 
In optimization designs the experiment is set-up in order to quantitate nonlinear 
cause-and-effect relationships and allow to increase the complexity of the 
mathematical modeling by adding square terms, and hence, to spot a minimum 
or maximum for our process. 
The DoE ends performing the experiments generated by the design 
approach and creating a mathematical model able to fit the results obtained by 
the experiments. Analysis of variance (ANOVA) can be used to assign 
significance to the effect of variables and interactions (32).  
 
1.8.1 Types of design 
For studying the effect of two factors (e.g., conductivity and pH) on 
process outputs (response variables), and including all combinations of high 
and low settings for both of these factors, a full factorial design can be used.  
A visualization of a design space for a full factorial design using two 
variables is a square with four corner experiments. The corners represent all 
combinations of the two factors at a high and a low level. A full factorial design 
also includes replicated center points between the high and the low level ([high 
+ low]/2) for both factors. The center point experiments are repeated at least 
three times and their main function is to measure variability. Center points will 
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also detect curvature but cannot assign a specific factor level as the cause of 
the curvature. 
A visualization of the design space for three factors would be a cube with 
each corner representing an experiment as represented in Figure 7. The number 
of experiments can be calculated by the formula N = 2k where k is the number 
of factors and N is the number of experiments. Full factorial designs support 
linear effects and all interactions so that each factor can be evaluated 
separately. For a two-level full factorial design the number of experiments is: 
N = 2k + 3 where the number 3 represent the center points. The center point 
allows detection of curvature, and is usually run in triplicate to estimate the 
noise. 
 
 
Figure 7: Three-factor full factorial design with three identical center-point 
experiments (32) 
 
For studies where four or more factors are of interest, such as in a 
robustness test or a screening study, it is quite common to employ fractional 
factorial designs. A fractional factorial design is constructed in a way that it 
will still be possible to identify main effects without acquiring the detailed 
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information that a full factorial design provides. The experiments are selected 
by using a symmetrical selection of corners, diagonals, and opposite diagonals. 
In general, a fractional factorial design can be designated as N = 2k–p, where 
N is the number of experiments, k is the number of factors to be investigated, 
and p the size of the fraction (1 = ½, 2 = ¼, 3 = ⅛, etc.). Plackett-Burman is 
one of the most common screening design. This designs using N = 4 × k 
number of runs to investigate up to (N-1) factors, can only be used to fit linear 
models. However, these models are in general heavily confounded by 
interaction effects but, if these interactions are negligible, the Plackett-Burman 
design can be used for efficient detection of large main effects. 
The Central Composite Design (CCD) contains a factorial or fractional 
factorial design with center points that is augmented of a value α, with a group 
of “star points” that allow estimation of curvature. If the distance from the 
center of the design space to a factorial point is ±1 unit for each factor, the 
distance from the center of the design space to a star point is |α| > 1. The 
specific value of α depends on certain properties desired for the design and on 
the number of factors involved. A central composite design always contains 
twice as many star points as there are factors in the design. The star points 
represent new extreme values (low and high) for each factor in the design 
(Figure 8). Central Composite Circumscribed (CCC) designs are the original 
form of the central composite design. The star points are at some distance α 
from the center based on the properties desired for the design and the number 
of factors in the design. The star points establish new extremes for the low and 
high settings for all factors. These designs have circular, spherical, or 
hyperspherical symmetry and require 5 levels for each factor.  
For those situations in which the limits specified for factor settings are 
truly limits, the Central Composite Inscribed (CCI) design uses the factor 
settings as the star points and creates a factorial or fractional factorial design 
within those limits (in other words, a CCI design is a scaled down CCC design 
with each factor level of the CCC design divided by α to generate the CCI 
design).  
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Central Composite Face Centered (CCF) requires 5 levels of each factor. 
In this design the star points are at the center of each face of the factorial space, 
so α= ± 1. This variety requires 3 levels of each factor. 
 
 
 
Figure 8: Central composite designs. (A) Two-factor CCC, (B) three-factor CCC, and 
(C) two-factor CCF design, and (D) three-factor CCF design (32) 
 
Figure 9 represents an example of a CCD design where a three-factor CFF 
design was used to optimize the elution conditions of a human immunoglobulin 
(IgG) bound to protein A. The three factors considered in the design are pH (3 
to 4), arginine concentration (0 to 1 M) and NaCl concentration (0 to 750 mM). 
The number of experiments to perform are seventeen including three replicates 
at the center point. 
 
 
 
 
Figure 9: Example of a CCF design proposed to optimize the elution condition of an 
IgG. Each sphere represent a single experiment to perform (32) 
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In the Box-Behnken design, experiments are performed on the edges 
instead of in the corners. This design avoids the corner settings with all factors 
simultaneously at high/low. Instead, the Box-Behnken design supports linear, 
interaction and quadratic effects for all model terms. The Box-Behnken design 
is suitable for three to seven factors and is especially useful for investigations 
of many (five to seven) parameters. This design is also suitable to use when 
some corner-point settings are not feasible because of process limitations (32-
33).  
 
1.9 High-Throughput Process Development (HTPD) 
Efficient development of the manufacturing process is a requirement in 
the biopharmaceutical industry as well as in other industries. A steadily 
increasing demand from regulatory authorities for a better understanding and 
control of manufacturing processes puts even more pressure on the 
development work. In HTPD, the initial evaluation of chromatographic 
conditions is performed in parallel, often using a 96-well plate format. Further 
verification and fine-tuning is typically performed using small columns before 
moving up to pilot and production scale. This approach to process development 
is performed using DoE. 
Designing purification processes for biopharmaceutical proteins at 
industrial scale is challenging, as there are numerous possible combinations of 
chromatography media and conditions. Fast process development has lately 
come in focus. In order to facilitate a “short time to market” the development 
of these processes should be performed as soon as possible even though only 
small amounts of pure API may be available. 
Chromatographic methods in packed bed format are widely used in 
Research & Development (R&D), process development and quality control for 
resin characterization. Chromatographic experiments are often time-
consuming and require large sample and test substance amounts. HTPD has 
emerged as a tool of interest in bioprocessing. The primary motivation for 
creating such a platform is that it allows to examine the effects and interactions 
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amongst the numerous process parameters that can impact step by performing 
larger number of experiments with relatively limited costs and time (34). 
The use of high-throughput methods such as parallel batch uptake 
experiments in microtiter plate format has the potential to substantially reduce 
both analysis time and material costs. Batch uptake assays have long been used 
in screening studies, but this study shows that analytical batch uptake methods 
can be used for determination of dynamic and total binding capacity for 
chromatographic resins (35-36-37). 
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2.  Aim of the work 
Most biotechnology unit operations are complex in nature with numerous 
process variables, feed material attributes, and raw material attributes that can 
have significant impact on the performance of the process. DoE-based 
approach offers a solution to this problem allowing for an efficient estimation 
of the main effects and the interactions with minimal number of experiments 
(38). 
 
This PhD work can be divided in two main parts. In the first part DoE and 
the HTPD approaches were adopted in order to optimize a production process 
of a therapeutic recombinant protein expressed in PER.C6 cell line (39).  
The macromolecule studied is a 340 kDa, glycosylated octameric human 
protein expressed in response to pro-inflammatory signals like Toll Like 
Receptor (TLR), Tumor Necrosis Factor α (TNFα) e Interleukin 1β (IL-1β). In 
particular, it is produced by many cell lines like mononuclear phagocytes, 
dendritic cells, fibroblasts endothelial cells. This proteins binds the 
complement protein C1q and specific microorganisms such as Aspergillus 
fumigatus and Pseudomonas aeruginosa. The interest for this protein is related 
to its function as an inflammatory marker in many diseases and to its use for 
the development of antifungals and antibacterials. 
In this PhD work the protein production process was further optimized in 
order to introduce a fully compliant GMP process. The optimization of the 
purification process can be driven by increasing the yield and by reducing the 
HCPs, residual DNA, protein aggregates and viral contamination. First, a new 
pilot scale disposable depth filtration technology as alternative to 
centrifugation for the harvest of the supernatant containing the protein of 
interest was evaluated. Second, the three chromatographic steps of the 
downstream process were optimized in terms of HCPs and rDNA reduction by 
screening and DoE approaches. In particular in the capture and polishing steps, 
these studies were used in order to introduce washing steps able to decrease 
impurities content. The same DoE approaches, were also used in the 
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intermediate step on hydroxyapatite to reduce the concentration of phosphate 
in elution buffer preventing the co-elution of the POI and the rDNA. 
Further strategy followed to reduce contaminants was the introduction of 
a membrane chromatographic step by flow-through applications. An 
evaluation of three chromatographic membranes was performed in order to 
adapt this technology for trace contaminant removal and virus clearance 
applications. The last aim was the introduction of viral reduction steps 
achieved by thermal inactivation and filtration, in order to satisfy ICH Q5A 
guidelines. In particular, three different virus removal filter were tested and 
sized in order to identify the best in terms of performances for the 
implementation in the full scale process. 
 
In the second part of the work, the DoE and HTPD technology were used 
as a systematic approach for the optimization of purification process for other 
recombinant proteins. These two innovative techniques, tested and developed 
during the optimization of the 340 kDa protein purification process, were used 
as a standardized “tool box” for the purification steps of other recombinant 
proteins or macromolecules such as plasmid DNA produced in 
microorganisms such as Escherichia coli (E. coli).  
The intention was to propose a comprehensive approach based on a step 
by step “decision tree” in order to lead the experimenter in a well defined path 
with the purpose of purifying and formulate any protein of interest. The protein 
used to test the procedure was a 13 kDa protein expressed in E. coli as 
inclusion bodies and used in rescue of the retinal function in glaucoma. This 
hydrophobic and basic protein is challenging to purify and to formulate in a 
stable and high concentrate formulation; therefore this model represents a 
good case study to test the efficiency of the systematic approach. 
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2.1 Confidentiality statement 
This PhD project was performed at Areta International S.r.l., an Italian 
biotech company specialized in contract development and GMP 
manufacturing of biodrugs and advanced therapy medicinal products. Areta is 
a multi-purpose service company that performs also contract research and is 
also co-developing a pipeline of products with other partners. For these 
reasons, some information related to the projects that have been performed as 
a service for the clients of the company are confidential and will not be 
disclosed in this work, such as the name of the drugs and their therapeutic 
indication. Anyway, the non-disclosure of such information does not represent 
a limitation to the aim of this work, which is strictly focused at the set-up of 
the methods that remain valid among similar variants of the same biological 
therapeutic class. 
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3.  Materials and methods 
 
3.1 DoE and HTPD approaches 
3.1.1 Design of experiment using the statistical software MODDE 
pro 11.0 
The experimental cycle of DoE using MODDE (Umetrics – MKS) 
consists of three phases. In the first phase a design of experiment is proposed 
where variables and their ranges, the responses and the objective of the design 
are defined. 
The second step corresponds to the analysis phase where data are 
explored, the raw data and the fit are reviewed and finally a model to explain 
the data is refined. The last phase correspond to the prediction phase where the 
model is used to predict the optimum area for operability.  
The statistical analysis, performed in order to evaluate the model fitting 
and to interpret the data obtained, are composed by the summary of fit plot, 
the coefficient plot, the interaction plot and the contour response surface plot. 
In the summary of fit plot four model statistics are considered. The R2 
value gives a measure of how much of the overall data variance the model can 
explain. R2 describes how well the model fits the current data. It can vary 
between 0 and 1, where 1 equals a perfect model and 0 corresponds to no model 
at all. A high R2 value is necessary for a good model but not sufficient on its 
own. A value of 0.75 indicates a rough but stable and useful model and an R2 
of 0.5 is a model with rather low significance. 
The Q2 value is a measure of how well the model will work for future 
predictions and it can usually vary between 0 and 1. The higher Q2 value, the 
better indicator of how well the model will predict new data. Q2 should be 
greater than 0.1 for a significant model and greater than 0.5 for a good model. 
Q2 is a better indicator of the usefulness of the model than R2 that should not 
exceed Q2 by more than 0.2–0.3 for a good model. 
The model validity is a value representing the lack of fit (a low value 
indicates that the model suffers from lack of fit). Model validity tests a variety 
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of problems and it is only available if replicated experiments have been 
performed. A model validity > 0.25 indicates a good model while a model 
validity < 0.25 indicates statistically significant model problems, such as the 
presence of outliers, an incorrect model, or a transformation problem. A low 
value may also indicates the missing of interaction or square term. When the 
pure error is very small (replicates almost identical), the model validity can be 
low even though the model is good and complete. 
The reproducibility compares the repeatability variation (replicates) with 
the overall variation (rest of the data). A reproducibility < 0.5 indicates that 
there is a large pure error and poor control of the experimental set-up (high 
noise level). 
In the coefficient plot, we can view the effect and importance of each 
model term indicated by the height (positive or negative) of the response 
change as the factor changes from its low to high level. The coefficient plot is 
also useful for model refinement. Thus, nonsignificant terms are identified by 
checking the confidence intervals (the noise contained in the confidence 
intervals). If the confidence interval covers zero the term is not significant. 
The interaction plot shows if there is no interaction between two factors. 
The factors are represented as two lines, if they are parallel no interaction can 
be observed, if not an interaction is evident. If the two lines are crossing, there 
is a strong interaction between the two factors. 
A response-surface plot is generated to get a graphical representation of 
the experimental region. From this plot, the most interesting area can be used 
to plan new experiments, verifying experiments, and to get a better 
understanding of the impact of large factor interactions. The response-surface 
plot is a tool for visualizing interaction and curvature effects (40).  
 
3.1.2 HTPD approaches 
The chromatographic HTPD approaches were performed using the 
vacuum manifold apparatus (Pall). First, a 50% (v/v) resin slurries were 
prepared and the desired volume of media were added to the 96 well acrowell 
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filter plate. The slurries were mixed frequently to avoid settling and 
inconsistent volume delivery to the plate. Subsequently a 1 mL collection plate 
was placed underneath the filter plate and the excess liquid from the well was 
removed by applying vacuum for ten seconds (0.34-0.69 bar). Afterwards, 
about five Resin Volumes (RV) of binding buffers were added to the well and 
then vacuum was applied. After the equilibration of the resins, the volumes of 
desired protein samples were loaded and the filter plate was mixed thoroughly 
using a plate mixer for 1 hour at room temperature to facilitate binding. After 
the incubation, Flow-Throughs (FT) fractions, containing unbound proteins, 
were collected. The resins were washed twice with a total of 10 RV of 
equilibration buffer. Each addition of buffer was mixed for 5 minutes before 
evacuating. Finally, retained proteins were eluted with 3 RV of elution buffers 
(Figure 10). 
 
 
 
Figure 10: Illustration of the workflow a HTPD approach. The process starts with the 
equilibration of the resin, the sample addition, the mixing and, after another washing 
step, the elution of the bound proteins (41) 
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3.2 Development and optimization of the production process 
of a 340 kDa human protein by High-Throughput (HT) 
techniques 
3.2.1 Upstream phase 
The PER.C6 cells were cultured in HyClone CDM4PerMAb™ medium (GE 
Healthcare) supplemented with 4 mM glutamine (Lonza) and 0.05% (v/v) of 
Poloxamer 188 (Sigma-Aldrich). The cells were thawed and seeded in the 
complete medium on a shaking flask at 37 °C in a humidified atmosphere 
containing 5% CO2. During the expansion phase, cells were monitored for cell 
count, viability and glucose concentration every two days and expanded in 
flasks until the total viable count (VCC) was at least 2×109 cells. The cells 
were further expanded on a 5 L working volume Cultibag RM (Sartorius) at a 
Viable Cell Count (VCC) of 0.5x106 cells/mL and grown on a Biostat RM 
(Startorius) using a rocking speed of 20 rpm, an angle of 6°, an airflow of 0.5 
L/min and a temperature of 37 °C. The cell culture was monitored daily for 
VCC, viability and glucose concentration. Viable cell count was performed 
with the NucleoCounter system (Sartorius) whereas the glucose concentration 
was determined with the Accu-Check Aviva device (Roche). The culture was 
supplemented with 0.5 L of complete Feed solution (75 g/L Amino Acid 
Powder Mark2 (AA Mark2) (Gibco), 31.2 g/L of Protein Expression Medium 
(PEM) (Thermo Scientific), 28.7 g CDM4PERMAb Feed Supplement 
(Gibco), 1.76 g tyrosine (Sigma-Aldrich), 1.2 g/L cysteine (Sigma Aldrich) 
and 0.1% Poloxamer 188 at days 3 and 5 and if necessary at day 7 starting from 
the inoculum. A total of 36×109 cells obtained from the 5 L Cultibag were used 
to inoculate four 25 L working volume Cultibag RM (Sartorius) containing 18 
L of complete medium supplemented with 2 g/L of glucose with an initial 
viable cell density of 0.5x106 cells/mL. The culture was monitored on a daily 
basis for glucose concentration, viability and pH. The culture was 
supplemented daily, starting from day 3, with 1 L of the feed medium. The 
culture was harvested when the viability dropped below 70%. The duration of 
the culture was about 10-14 days defined by the viability. 
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3.2.2 New disposable pilot scale depth filtration technologies 
A volume of 10 L of PER.C6 fermentation was loaded on Millistak+ POD 
(D0HC) (Merck-Millipore) and on Supracap 100 (Pall) connected in series 
with a 0.022 m2 0.22 µm Mini Kleenpak supor EAV membrane (Pall) 
disposable filter. Both depth filters have an area of 0.05 m2 and the same 
construction materials, the retention range of the Millistak+ filter is 9-0.6 µm 
while for the Supracap it is 0.8-0.4 µm. The material of the 0.22 µm filter is 
PolyEtherSulfone (PES) with an area of 0.026 m2. After the laboratory-scale 
screening, 100 L of the same high cell density fed batch cultivations was 
processed using two Stax disposable depth filter system (Medium-single layer, 
P series, superficial area 1 m2, retention range 0.8-0.4 µm) (Pall) connected in 
series with a 0.22 µm Kleenpak Nova capsule filter PES supor EAV membrane 
(T style, with 2,16 m2 of superficial area) (Pall). Both systems were connected 
to a peristaltic pump and a manometer. Before loading, the system was washed 
with Water For Injection (WFI). The broth was loaded and processed with a 
flux of 100 L/m2/h. Pressure and the filter capacity were monitored throughout 
the process.  
 
3.2.3 Determination of the Q Sepharose Fast Flow (FF), 
Hydroxyapatite (HA) and Phenyl Sepharose FF binding capacity 
Three Tricorn columns 10/50 mm (GE) were used to pack 1 mL of Q 
Sepharose FF (GE), CHT ceramic HA type I 40 µm (Bio-Rad) and Phenyl 
Sepharose FF High sub (GE). The buffer used for the equilibration of Q 
Sepharose was 50 mM Tris-HCl, 400 mM NaCl pH 7, 10 mM sodium 
phosphate buffer pH 7 for the HA and 50 mM Tris-HCl, 2 M NaCl pH 7 for 
the Phenyl Sepharose. The purification was performed using the ÄKTA 
purifier system (GE) applying a linear flow rate of 80 cm/h. The Q Sepharose 
was loaded with 12 mL of PER.C6 supernatant, the HA with 12 mL of the 
eluate from Q Sepharose and the phenyl Sepharose with 12 mL of eluate from 
HA. All the samples were preventively diluted with equilibration buffers in 
order to have 0.25 mg/mL as concentration of protein of interest. NaCl was 
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added from a 5 M stock to HA eluate in order to reach the concentration of 2 
M of NaCl. The FT was collected in twelve 1 mL fractions. The WB of the 
fractions was analyzed with Image J software in order to determine the 
concentration of the protein of interest.  
 
3.2.4 Optimization of HA purification step with an HTPD approach 
In order to improve the elution conditions on the HA, 5 mL of a 50% 
slurry composed of CHT ceramic HA 40 µm type I and 0.1 M NaOH were 
centrifuged at 1000 × g. Twenty-two wells were prepared as described in 
paragraph 3.1.2 with 200 µL of 50 % slurry (100 µL of resin). The wells were 
washed with 50 mM Tris-HCl, 400 mM NaCl pH 7 and then 200 µg of Q 
Sepharose eluate, containing the protein of interest at the concentration of 1 
mg/mL, was added to each well. After 1 h of incubation the vacuum was 
applied and the dry resins were resuspended with three RV of 10 mM sodium 
phosphate buffer pH 7 repeating this step three times. An onion D-optimal 
design of experiment was planned in order to set-up an elution buffer matrix 
using as variables pH and sodium phosphate buffer concentrations. Both 
factors are quantitative with a pH range from 6.5 to 7.5 and a phosphate buffer 
concentration range from 10 to 350 mM. Figure 11 resumes the worksheet 
generated by MODDE planning the concentrations and pH of the elution 
buffer in the DoE. Three RV (300 µL) of the 28 different elution buffer were 
used to resuspend the dry resins and then the vacuum was applied in order to 
collect the FTs.  
The responses considered in this DoE were HCPs, residual DNA and the 
protein of interest content. 
 
 
 46 
 
 
Figure 11: Onion design of the DoE performed for the optimization of HA purification 
step. The onion design represent the experimental space as comprising a number of 
sub-spaces called “layers” or “shells”. This design allows to select a diverse range of 
experiments with uniform coverage across the experimental domain 
3.2.5 Optimization of Q Sepharose FF and Phenyl Sepharose FF 
(high sub) chromatographic steps  
In order to reduce HCPs in the Q Sepharose FF eluted fraction, a 
screening of different washing buffers containing different components 
(arginine (Sigma), MgCl2 (Sigma), ethanol (Sigma), glycerol (Carlo Erba) and 
polysorbate 20 (Sigma)) at different concentrations was performed. The 
screening was performed with the vacuum manifold apparatus. An 1 mL 
receiver plate was placed at the bottom of the apparatus and upside a 96 well 
acrowell filter plates. A volume of 200 µL of Q Sepharose FF was added to 
every well of the plate and then was washed with equilibration buffer 
composed by 50 mM Tris-HCl, 400 mM NaCl pH 7. A volume of 200 µL of 
PER.C6 supernatant was loaded and, after a washing of five RV with 
equilibration buffer, the resins were washed with one volume of 50 mM Tris-
HCl pH 7 with the addition of different excipients. Table II resumes the 
excipients concentrations used in the work. 
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Table II: Excipients concentrations used in washing buffer during capture step on Q 
Sepharose FF 
 
After the washing step, the protein of interest was eluted with two RV of 
50 mM Tris-HCl, 650 mM NaCl pH 7. The eluates were analyzed by ELISA 
test to determine the yields of the protein of interest and HCPs. 
A similar approach was performed to reduce HCPs in Phenyl Sepharose 
FF eluate and to increase the protein yield. The apparatus was prepared as the 
Q Sepharose FF experiment. A matrix of arginine and NaCl concentration in 
loading buffer (50 mM Tris-HCl pH 7) and in sample fraction was designed to 
identify the best combination able to reduce HCPs and increase yield. 
A CCF design of experiment was planned as for the optimization of HA 
elution described in the previous paragraph. The range of the two factors 
considered was 0.5 to 2 M for NaCl concentration and 25 to 500 mM for 
arginine concentration. Table III resumes the worksheet generated by the 
software. The numbers of run are 22, composed by three center points and 
eight experiments with one replication for each test. 
The resins were washed with two RV of loading buffer, then, samples 
were loaded (concentration of the protein of interest 1 mg/mL) and after two 
RV of re-equilibration the protein was eluted with WFI.  
The eluates were analyzed by ELISA test to determine the yields of the 
protein of interest and HCPs.  
 
   (mM) 
Excipients 
0.9 1.8 4.5  5 10 50 100 200 342 428 500 684 856 1370 1710 
  Arginine 
 
               
   MgCl2                
  Glycerol                
  Ethanol                
Polysorbate 
       20 
               
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Table III: DoE of the Phenyl Sepharose FF elution optimization 
 
Exp No Run Order [arginine] (mM) [NaCl] (M) 
1 8 25 0.5 
2 3 500 0.5 
3 18 25 2 
4 7 500 2 
5 1 25 1.25 
6 11 500 1.25 
7 17 262.5 0.5 
8 22 262.5 2 
9 2 262.5 1.25 
10 5 262.5 1.25 
11 21 262.5 1.25 
12 6 25 0.5 
13 15 500 0.5 
14 16 25 2 
15 19 500 2 
16 10 25 1.25 
17 12 500 1.25 
18 14 262.5 0.5 
19 20 262.5 2 
20 4 262.5 1.25 
21 13 262.5 1.25 
22 9 262.5 1.25 
 
3.2.6 Reduction of HCPs and DNA: introduction of a membrane 
chromatographic step 
A single-use, membrane-based ion exchanger chromatographic step was 
proposed in order to reduce the contaminants after Q Sepharose FF elution. 
The table IV refers to two different membrane anion exchangers and one 
cation exchanger that were screened in this work. 
Pall acrodiscs were conditioned with 4 mL of NaOH, 4 mL of NaCl and 
10 mL of equilibration buffer 50 mM Tris-HCl, 650 mM NaCl pH 7 while 
Chromasorb was washed with equilibration buffer. 
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Table IV: Single-use membrane-based ion exchanger proposed in the work. * 
Polymeric Primary Amine (PPA) **Ultra-high molecular weight PolyEthylene (UPE)  
 
A volume of 2 mL of Q Sepharose FF eluate (concentration of protein of 
interest 1 mg/mL) was loaded on each filter at a 1 mL/min flux using the 
ÄKTA Purifier system (GE). Resin FT was analyzed for yield, HCPs and DNA 
content. 
 
3.2.7 Feasibility study of viral clearance by thermal inactivation and 
Normal Flow Filtration (NFF) 
The fraction from the HIC step at the concentration of 0.4 mg/mL was 
processed for viral thermal inactivation at 60±2 °C for 4.0±0.1 hours under 
continuous stirring. Protein yield, aggregation (SEC) and reduction of HCPs 
evaluation were assessed. Virus clearance was evaluated by a NFF through the 
screening of three different prefiltration 0.1 µm filter and three 20 nm filters. 
The prefilter used for the work was Viresolve pro V shield 3.1 cm2 (Merck-
Millipore), Millipore express SHR optiscale 3.1 cm2 (Merck-Millipore) and 
the prototype V shield H31 3.1 cm2 (Merck-Millipore). The 20 nm filters used 
for the screening were: Viresolve Pro 3.1 cm2 (Merck-Millipore), Ultipor VF 
grade DV20 9.6 cm2 (Pall) and Pegasus SV4 virus removal 9.6 cm2 (Pall). The 
combinations of filters and prefilters are resumed in table V. 
 
 
 
 
 
Membrane Manufacturer Membrane 
Pore 
size 
Bed 
volume 
Ion 
exchanger 
Acrodisc 
Mustang Q 
Pall PES 
0.8 
µm 
0.18 ml 
Q (anion 
exchanger) 
Chromasorb Merck UPE** 
0.65 
µm 
0.08 ml  PPA* 
Acrodisc 
Mustang S 
Pall PES 
0.8 
µm 
0.18 ml 
S (cation 
exchanger) 
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Table V: Different combination of prefilters and filters used in the screening 
 
                       20 nm Filter 
  Viresolve V Pro DV 20 SV 4 
0.1 µm  
Filter 
V SHIELD  × × 
SHR  × × 
V SHIELD H 31  × × 
NONE    
 
The screening was performed using a peristaltic pump at a constant 
pressure of 2 bar. All the conditions were compared for yield and by plotting 
the flux decay (J actual/J initial) vs loading (L/m2) and simple capacity 
evaluation was carried out by measuring the volume filtered vs the time at 
constant operating pressure. The equation for calculating Vmax (total volume 
that can be filtered per unit membrane area) is:  
𝑡
𝑉
=
𝑡
𝑉𝑚𝑎𝑥
+
1
𝑄𝑖
 
(t is the time, V is cumulative volume filtered and Qi is the initial flux).  
The minimum area for 50 L scale-up batch size, to process in about four 
hour, was determined by the formula: 
𝐴𝑚𝑖𝑛 =
𝐵𝑎𝑡𝑐ℎ 𝑉𝑜𝑙𝑢𝑚𝑒
𝑉75
+
𝐵𝑎𝑡𝑐ℎ 𝑉𝑜𝑙𝑢𝑚𝑒
𝑄𝑖 × 𝑝𝑟𝑜𝑐𝑒𝑠𝑠 𝑡𝑖𝑚𝑒
 
where V75 is 0.5×Vmax and it is also defined as the volumetric throughput 
where Q=Qi×0.25. The first term of the equation is related to filter capacity, 
while the second is linked to productivity (process speed). If the relative Vmax 
is low and Qi is high, the second term in the equation is negligible compared 
to the first one, the filters are sized based on capacity (42). 
 
3.2.8  Performance test of the downstream process 
The complete downstream process was performed at a 25 L scale. Table 
VI resumes all the investigated downstream process steps. In order to assess 
the process reproducibility all the steps were analyzed in terms of yield, HCPs 
and rDNA content. 
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Table VI: Complete downstream process performed on a 25 L scale 
STEP 
Apparatus/ 
Column 
Flux/ 
Pressure 
Procedure 
Volume/ 
dimension 
1.Deph 
filtration 
Stax (PALL) 100 L/m2/h 75 mM NaCl washing buffer 50 L/m2 
2.Q 
Sepharose 
FF 
(Q) 
ÄKTA 
Purifier-Pilot 
BPG Column 
(200/500) 
1: 34 cm/h 
 
 2: 8.5 cm/h 
 3: 34 cm/h 
4: 34 cm/h 
 
5: 34 cm/h 
6: 34 cm/h 
 
1: 3 CV AQ (50 mM Tris-
HCl, 400 mM NaCl pH 7) 
2: Load sample 
3: 1 CV AQ 
4: 1 CV WQ (Buffer A + 50 
mM Arg) 
5: 2 CV AQ 
6: Elution with BQ (50 mM 
Tris-HCl, 650 mM NaCl pH 
7)  
 
5 L  
3.Mustang Q 
(MQ) 
Mustang Q 
(Pall) - 
peristaltic 
pump 
100 
mL/min 
1: 100 mL NaOH 1 M 
2: 100 mL NaCl 1M 
3: 300 mL BQ 
4: Loading Q eluated fraction 
 
60 mL 
4.HA 
ÄKTA 
Purifier-Pilot -
BPG Column 
(100/500) 
76 cm/h 
1:  3 CV AHA (50 mM Tris-
HCl, 50 mM sodium 
phosphate buffer ph 7.5) 
2: Loading MQ FT after 
addition of 50 mM sodium 
phosphate buffer (final 
concentration) 
3: Wash with 2 CV AHA and 
collect the FT 
4: Elute DNA with 3 CV 500 
mM sodium phosphate buffer 
ph 7.5 
 
1.25 L 
5.Phenyl 
Sepharose 
FF 
(HIC) 
ÄKTA 
Purifier-Pilot 
BPG Column 
(100/500 25L) 
76 cm/h  
 
1: 3 CV  AHIC (50 mM Tris-
HCl, 2 M NaCl, 50 mM 
arginine ph 7) 
2: Load HA FT + 2 M NaCl 
and 50 mM arginine (final 
concentrations)  
3:  2 CV AHIC 
4: Eluate with water for 
injection (WFI) 
 
1.25  L 
6.Viral 
inactivation 
and viral 
clearance 
Thermal 
inactivation + 
0.1 µm 
opticap 
millistax 
(Merck-
millipore)+20 
nm Filtration 
DV20 (Pall) 
Operating 
pressure= 2 
bar 
Thermal inactivation: 4 h 
@60° C 
Viral clearance: NFF @ 2 bar 
0.1 µm: 
35 cm2 
(2x 47mm 
capsule); 
0.07 m2 
DV20 
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STEP 
Apparatus/ 
Column 
Flux/ 
Pressure 
Procedure 
Volume/ 
dimension 
7. 
TFF+ 0.2µm 
filtration 
Novasep 
Cassette 
TangenX (100 
kDa) 
ΔP=0.7 
bar 
7 volume exchange and 
concentration to 2,5 mg/L PBS 
10 mM sodium phosphate 
buffer, 150 mM NaCl pH 7 
 
0.1 m2  
 
3.2.9 Scale-up of the fully GMP recombinant protein downstream 
process 
The 100 L cell culture from four 25 L culture was harvested by depth 
filtration on a 2 m2 STAX filter (Pall) followed by sterile filtration using a 2.16 
m2 0.22 µm Kleenpak Nova capsule filter (Pall). The non-purified bulk was 
stored at 2-8 °C in single use containers until further processed and no longer 
than 4 days.  
The 100 L cell culture harvest was loaded on 20 L Q-Sepharose FF (GE 
Healthcare) previously packed on a BPG 300/500 column (GE Healthcare). 
The column equilibrated with 3 CV buffer AQ (50 mM Tris/HCl, 400 mM 
NaCl pH 7.0) at a linear flow rate of 34 cm/h. The non-purified bulk was loaded 
at 8.5 cm/h followed by a washing step of 1 CV of buffer AQ, 1 CV of buffer 
WQ (50 mM Tris/HCl, 50 mM arginine pH 7.0) and 2 CV of buffer AQ at 34 
cm/h. The protein of interest was eluted in a single peak with a step gradient 
of buffer BQ (50 mM Tris/HCl, 650 mM NaCl pH 7.0) at the same linear flow 
rate. The eluted fraction was online sterile filtered with 0.22 µm filter (Pall) 
and stored at 2-8 °C in single use containers. The column was subsequently 
regenerated with 1 CV of buffer CQ (50 mM Tris/HCl, 1 M NaCl pH 7.0) and 
2 CV of 20% v/v ethanol. 
The eluted fraction from Q Sepharose FF was processed on a 140 mL 
Mustang Q XT membrane filter (Pall). The membrane was previously 
equilibrated 2 L of buffer BQ. The flow through (FT) was collected and filtered 
at 0.22 µm (Pall) and stored in single use containers at 2-8 °C. 
The sample obtained from Mustang Q step was prepared for loading on 
the HA by adding 50 mM sodium phosphate, final concentration. A volume of 
5 L of Macroprep Hydroxyapatite CHT-1, 40 µm  (Bio-Rad) was packed on a 
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BPG 200/500 column (GE Healthcare), equilibrated with buffer AHA (50 mM 
sodium phosphate, 50 mM Tris/HCl pH 7.5). The sample was loaded at a linear 
flow rate of 76 cm/h and the protein of interest was eluted with 2 CV of buffer 
AHA. The eluted fraction containing the POI was diluted 1:2 with buffer AHA 
and then filtered through a 0.22 µm filter (Pall) and stored in single use 
containers at 2-8 °C. 
The sample obtained from the HA step was further processed on 5 L 
Phenyl Sepharose FF high substitution column (GE Healthcare) packed on a 
BPG 200/500 column (GE Healthcare). In order to achieve the protein binding, 
the NaCl concentration was adjusted to 2 M and the arginine concentration to 
50 mM. The sample was loaded on the column previously equilibrated with 
buffer AHIC (50 mM sodium phosphate, 2 M NaCl and 50 mM arginine pH 
7.0) at a linear flow rate of 76 cm/h, followed by washing with 2 CV of buffer 
AHIC. Elution of protein of interest was performed with WFI in approximately 
1.7 CV. The eluted sample was sterile filtered (Pall) and stored at 2-8 °C until 
further processed. 
The fraction from the HIC step was processed for viral thermal 
inactivation at 60±2 °C for 4.0±0.1 hours under continuous stirring. The 
solution was filtered through a 0.22 µm filter (Pall) and subsequently on a 
millipak-20 100 cm2 0.1 µm filter (Merck Millipore). The viral removal by 
filtration was performed on two 0.07 m2 20 nm Ultipor® VF Grade DV20 filter 
(Pall) at a constant pressure of 2 bar with a flux of 24 LMH. The sample was 
filtered and stored at 2-8 °C in single-use containers until further processed. 
The fraction obtained from the viral removal filtration was formulated at 
2.5 mg/ml by tangential flow filtration on a 0.1 m2 single use cassette with a 
cut-off of 100 kDa (TangenX) in 10 mM sodium phosphate, 150 mM NaCl pH 
7.0. The final product was recovered from the system and sterile filtered at 0.22 
µm and stored at 2-8 °C. 
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3.3 Development of a systematic approach for the purification 
of a 13 kDa human protein expressed in E. coli 
3.3.1 E. coli cultivation, inclusion bodies preparation and refolding 
of the protein of interest 
E. coli strain expressing the 13 kDa protein was cultivated in 2XYT 
medium (16 g/L Soytone (Difco), 10 g/L yeast extract (Difco) and 5 g/L NaCl 
(Sigma)) with the addition of 50 mg/L of kanamycin. A preinoculum of 50 mL 
(5% v/v final culture volume) was prepared and used to inoculate 1 L of the 
broth. The expression of the protein was induced by adding 1 mM isopropyl-
β-D-1-thiogalactopyranoside (IPTG) (Sigma) and 20 mM MgCl2 (Sigma) 
when the cultivation reached an optical density OD600 nm of 0.5. After 15 hours 
of incubation at 37° C with a shaking of 250 rpm, the culture was harvested 
by centrifugation. 
The pellet was resuspended with 5 mL/g of lysis buffer (0.1 M Tris-HCl, 
1 mM ethylenediaminetetraacetic acid (EDTA), 3 mM MgCl2 pH 7) using an 
homogeneizator. The homogenate was subsequently sonicated with ten pulse 
of one minute. Between every pulse, the sample was equilibrated in ice for one 
minute. After the lysis step, half volume of Triton buffer (6% (v/v) of Triton 
X100 (Sigma), 1.5 M NaCl, 60 mM EDTA) was added to the lysate and the 
mixture was incubated at room temperature (R.T.) for 30 minutes under 
continuous stirring. At the end of incubation the mixture was centrifuged at 
15000 × g for 20 minutes at 4 °C. In order to prepare the inclusion bodies the 
procedure described was performed two times. Subsequently, the inclusion 
bodies pellets were resuspended with inclusion body wash buffer (0.1 M Tris-
HCl, 20 mM EDTA, pH 7) and centrifuged as previously described. The 
washing step was performed three times and, consequently, 5 mL/g of 
solubilization buffer (6 M guanidine-HCl (Sigma), 0.1 M Tris-HCl, 1 mM 
EDTA, 0.1 M dithiothreitol (DTT) (Sigma), pH 8) were used to dissolve the 
pellets. After three hours of incubation on a rotating wheel, the mixture was 
brought at pH 3 with 37% (v/v) HCl and then centrifuged for 10 minutes at 
15000 × g. The supernatant was dialyzed against 6 M guanidine-HCl pH 3 at 
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4 °C replacing the buffer four times every 12 hours. After dialysis, total 
proteins were quantified using the bicinchoninic acid (BCA) assay. In order to 
obtain a final concentration of guanidine-HCl of 200 mM the refolding buffer 
(0.1 M Tris-HCl, 1 M arginine, 5 mM EDTA, 0.61 g/L oxidized glutathione, 
1.53 g/L reduced glutathione pH 9.3) was prepared. Every hour 50 μg/mL of 
resolubilized protein was added to refolding buffer under vigorous stirring. 
 
3.3.2 Arginine removal step: screening of suitable buffers  
Arginine was used as chemical chaperone in order to help the refolding 
process, but, due to its high concentration it could interfere with the following 
purification steps. In order to reduce the amount of this amino acid, four 
alkaline dialysis buffers were evaluated (0.1 M Tris-HCl pH 9.5, 0.1 M 
carbonate buffer pH 9.5, 0.1 M glycine-NaOH pH 9.5, 0.1 M phosphate buffer 
pH 8). The dialysis were performed with a 7 kDa membrane (SnakeSkin 
dialysis tubing – Thermo Scientific) replacing the buffer three times every 
twelve hours. Protein stability was tested measuring the total protein content 
with BCA analysis, the protein of interest with ELISA test and performing 
turbidity assay measuring the absorbance at 410 nm. 
 
3.3.3 Platform set-up for protein stability testing: sample 
preparation for chromatography (platform n°1) 
Some variables such as pH, NaCl concentration, temperature, time and 
the starting total protein concentration could affect protein stability. In order 
to test how these factors can alter protein composition in 0.1 M Tris-HCl 
buffer, used during the chromatographic steps, a DoE based on a fractional 
factorial V+ resolution was performed. Table VII resumes the DoE performed. 
pH range of the samples was forced outside the buffer capacity of Tris-HCl (7-
9.5), choosing 4 and 10.5 as limits of the test, NaCl concentration range was 
set between 0 to 1 M, incubation time between 0 to 2 hours and total protein 
concentration between 0.1 to 0.75 mg/mL. The temperature was set as 
multilevel quantitative variable at 4 and 20 °C. 
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Table VII: DoE for the protein stability evaluation 
Exp 
No 
Run 
Order 
pH 
[NaCl] 
(M) 
Time 
(h) 
[POI] 
(mg/mL) 
Temp 
(°C) 
1 35 4 0 0 0.1 20 
2 37 10.5 0 0 0.1 4 
3 18 4 1 0 0.1 4 
4 24 10.5 1 0 0.1 20 
5 16 4 0 2 0.1 4 
6 5 10.5 0 2 0.1 20 
7 38 4 1 2 0.1 20 
8 1 10.5 1 2 0.1 4 
9 34 4 0 0 0.75 4 
10 33 10.5 0 0 0.75 20 
11 30 4 1 0 0.75 20 
12 36 10.5 1 0 0.75 4 
13 13 4 0 2 0.75 20 
14 21 10.5 0 2 0.75 4 
15 8 4 1 2 0.75 4 
16 12 10.5 1 2 0.75 20 
17 32 7.25 0.5 1 0.425 4 
18 20 7.25 0.5 1 0.425 4 
19 7 7.25 0.5 1 0.425 4 
20 3 4 0 0 0.1 20 
21 31 10.5 0 0 0.1 4 
22 9 4 1 0 0.1 4 
23 22 10.5 1 0 0.1 20 
24 11 4 0 2 0.1 4 
25 17 10.5 0 2 0.1 20 
26 28 4 1 2 0.1 20 
27 27 10.5 1 2 0.1 4 
28 29 4 0 0 0.75 4 
29 26 10.5 0 0 0.75 20 
30 2 4 1 0 0.75 20 
31 10 10.5 1 0 0.75 4 
32 25 4 0 2 0.75 20 
33 4 10.5 0 2 0.75 4 
34 19 4 1 2 0.75 4 
35 23 10.5 1 2 0.75 20 
36 6 7.25 0.5 1 0.425 4 
37 14 7.25 0.5 1 0.425 4 
38 15 7.25 0.5 1 0.425 4 
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One hundred μg of total proteins content were used for each point and 
conductivity was corrected adding a stock solution of 5 M NaCl in order to 
reach the desired concentration and pH was reduced or increased using 4 M 
HCl or 4 M NaOH respectively. The responses considered in this work were 
the total protein amount analyzed by BCA assay.  
 
3.3.4 Chromatographic capture step: HTPD platform development 
(platform n°2) 
An HTPD panel comprising cationic, anionic and mixed mode 
chromatographic media was proposed in order to build up a fast method to 
identify a resin able to significatively bind the protein of interest. Table VIII 
resumes the media and their properties. 
 
Table VIII: Chromatographic media screened in the capture step 
 
 Exchanger 
Bead 
diameter 
Matrix 
materials 
pH 
stability 
SP Sepharose 
FF HP (GE) 
SP 
Sulfopropyl 
(strong cationic) 
34 μm Agarose 
 
3-14 
Eshmuno S 
(Merck) 
ES 
Sulfo 
(strong cationic) 
75-95 μm 
Hydrophilic 
polyvinyl ether 
 
2-12 
Poros XS 
(Applied 
biosystems) PS 
Sulfopropyl 
(strong cationic) 
50 μm 
Polystyrene-
divinylbenzene 
1-14 
Nuvia S Bio-
Rad) 
NS 
Sulfo 
(strong cationic) 
85 μm 
Unosphere 
(cross liked 
polymer) 
2-14 
CM Sepharose 
FF (GE) 
CM 
Carboxy 
methyl 
(weak cationic) 
90 μm Agarose 3-14 
Fractogel SO3- 
(Merck) 
FS 
Sulfo 
(Strong Cationic) 
40-90 μm 
Methacrylate 
polymer 
 
2-12 
Eshmuno HCX 
(Merck) 
EX 
Sulfo, 
carboxy and 
phenyl  
(mixed mode) 
75-95 μm 
Hydrophilic 
polyvinyl ether 
2-12 
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Exchanger 
Bead 
diameter 
Matrix 
materials 
pH 
stability 
HA (Bio-Rad) 
HA 
Ca2+, PO4-, 
OH-  
(mixed mode) 
40 μm Hydroxyapatite 6.5-14 
Nuvia Q (Bio-
Rad) 
NQ 
Quaternary 
amine 
(strong cationic) 
 
μm 
Unosphere 
(cross liked 
polymer) 
2-14 
Q Sepharose 
FF (GE) 
Q 
Quaternary 
amine  
(strong cationic) 
 
90 μm Agarose 3-14 
Poros HQ 
(Applied 
biosystems) 
PQ 
Quaternary 
amine 
(strong cationic) 
 
50 μm 
Polystyrene-
divinylbenzene 
1-14 
 
The screening approach was performed as described in paragraph 3.1.2 
using 50 µL of resins with two levels full factorial DoE. The variables 
considered in this work were pH, conductivity and total protein loading. Table 
IX resumes the entire screening and sample preparation. The samples pH range 
was set from 9.5 to 7 for the cationic and mixed mode resins while 10.5 to 7 
for anionic. NaCl concentration was set from 0 to 1 M and total protein loaded 
set from 50 to 360 µg. As described in the previous paragraph a concentrated 
solution of 5 M NaCl was used to modify the salt concentrations and 4 M HCl 
and 4 M NaOH to adjust pH. The FTs were analyzed by dot blot analysis, 
ELISA test and BCA assay. 
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Table IX: DoE matrix performed in capture step HTPD approach. Each box contains 
information about pH and NaCl concentration (M) of the sample and equilibration 
buffer (pH/[NaCl]) 
 
 50 µg load 360 µg load 205 µg load 
SP 7/0 9.4/0 7/1 9.4/1 7/0 9.4/0 7/1 9.4/1 8.25/0.5 8.25/0.5 8.25/0.5 
ES 7/0 9.4/0 7/1 9.4/1 7/0 9.4/0 7/1 9.4/1 8.25/0.5 8.25/0.5 8.25/0.5 
PS 7/0 9.4/0 7/1 9.4/1 7/0 9.4/0 7/1 9.4/1 8.25/0.5 8.25/0.5 8.25/0.5 
NS 7/0 9.4/0 7/1 9.4/1 7/0 9.4/0 7/1 9.4/1 8.25/0.5 8.25/0.5 8.25/0.5 
CM 7/0 9.4/0 7/1 9.4/1 7/0 9.4/0 7/1 9.4/1 8.25/0.5 8.25/0.5 8.25/0.5 
FS 7/0 9.4/0 7/1 9.4/1 7/0 9.4/0 7/1 9.4/1 8.25/0.5 8.25/0.5 8.25/0.5 
EX 7/0 9.4/0 7/1 9.4/1 7/0 9.4/0 7/1 9.4/1 8.25/0.5 8.25/0.5 8.25/0.5 
HA 7/0 9.4/0 7/1 9.4/1 7/0 9.4/0 7/1 9.4/1 8.25/0.5 8.25/0.5 8.25/0.5 
Q 7/0 10.5/0 7/1 10.5-1 7/0 10.5/0 7/1 10.5/1 8.75/0.5 8.75/0.5 8.75/0.5 
NQ 7/0 10.5/0 7/1 10.5-1 7/0 10.5/0 7/1 10.5/1 8.75/0.5 8.75/0.5 8.75/0.5 
PQ 7/0 10.5/0 7/1 10.5-1 7/0 10.5/0 7/1 10.5/1 8.75/0.5 8.75/0.5 8.75/0.5 
 
3.3.5 Elution conditions optimization on anionic exchangers 
(platform n°3) 
A similar DoE approach, as those mentioned in paragraphs 3.3.3 and 3.3.4, 
was proposed in order to optimize elution conditions of the three anionic resins 
(Nuvia Q, Q Sepharose FF and Poros HQ). The variables considered for elution 
buffers were the pH (range 10.5-6), the NaCl concentration (range 0-1 M) and 
the buffer nature as qualitative variable (100 mM of Tris or sodium phosphate) 
in order to plan a two level full factorial design. Starting sample represented 
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refolded protein dialyzed against 0.1 M Tris-HCl pH 9.5. First, 50 µL of resins 
were equilibrated with 0.1 M Tris-HCl pH 10.5 and subsequently 50 µg of total 
proteins were loaded. The buffers described in Table X were used for the 
elution step. Eluted fractions were quantified in terms of POI and HCPs 
content. 
 
Table X: Elution buffers composition in the capture step 
Exp No Run Order pH [NaCl] Buffer 
1 9 6 0 Phosphate 
2 6 10.5 0 Tris 
3 5 6 1 Phosphate 
4 2 10.5 1 Tris 
5 10 6 0 Phosphate 
6 7 10.5 0 Tris 
7 8 6 1 Phosphate 
8 11 10.5 1 Phosphate 
9 3 8.25 0.5 Phosphate 
10 4 8.25 0.5 Phosphate 
11 1 8.25 0.5 Phosphate 
 
3.3.6 Scale-up of the anionic capture step 
The binding capacity of the three media considered in paragraph 3.3.5 was 
determined adopting the same approach described in paragraph 3.2.3. 
Subsequently, one milliliter of the three anionic resins, was packed in a Tricorn 
10/50 column (GE) and equilibrated with ten volumes of 0.1 M Tris-HCl pH 
10.5 at the linear flow rate of 76 cm/h. Refolded protein, dialyzed against 0.1 
M Tris-HCl pH 9.5, was loaded at the same flow and then eluted using a linear 
gradient of ten CV from 0 to 100% of elution buffer (100 mM sodium 
phosphate buffer, 1 M NaCl pH 6). During the elution, fractions of 0.5 mL 
were collected and subsequently analyzed by dot blot in order to detect the 
peak containing the protein of interest. The linear gradient allowed the 
identification of the percentage of elution buffer in order to optimize a stepwise 
elution performed on 5 mL resin packed on a XK 16/20 column (GE). In 
particular, part of the E. coli HCPs and rDNA were eluted at 15% of elution 
buffer while the POI was eluted at the 37%. Others contaminants were 
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removed after the regeneration of the column with the 100 mM phosphate 
buffer, 1 M NaCl pH 6. The HCPs content, total protein and POI content were 
quantified in the fraction containing the 13 kDa protein.  
 
3.3.7 Chromatographic intermediate/polishing step: HTPD 
platform development (platform n°4) 
In order to introduce a second purification step able to reduce HCPs and 
rDNA an iterative approach was followed. First, all the cationic resins FTs 
samples, obtained in platform n° 2, were quantified for HCPs and rDNA 
content. The aim was to select a media for the introduction of a flow-through 
chromatographic step to identify conditions where contaminants were 
eliminated. Then, since HA resulted as a media able to highly bind the protein 
of interest, a three variable DoE was prepared to select the best elution 
condition. The first variable considered was the sodium phosphate 
concentration (range from 10 to 500 mM), second CaCl2 concentration (from 
0 to 20 ppm) and third the NaCl concentration (from 0 to 1 M). Also in this 
case, 50 µL of resin and 50 µg of POI eluted from Nuvia Q were used in the 
HTPD approach. Initially the resins were washed with 10 mM sodium 
phosphate buffer pH 7 subsequently the sample was loaded and finally the 
resins were washed with buffers described in Table XI used for the elution 
steps. 
 
Table XI: CCF design for the optimization of the elutions in polishing/intermediate 
step 
Exp No Run Order [Sodium phosphate] [NaCl] [Ca2+] 
1 17 10 0 0 
2 16 500 0 0 
3 8 10 1 0 
4 12 500 1 0 
5 11 10 0 20 
6 14 500 0 20 
7 3 10 1 20 
8 6 500 1 20 
9 4 10 0.5 10 
10 10 500 0.5 10 
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Exp No Run Order [Sodium phosphate] [NaCl] [Ca2+] 
11 2 255 0 10 
12 5 255 1 10 
13 9 255 0.5 0 
14 15 255 0.5 20 
15 1 255 0.5 10 
16 13 255 0.5 10 
17 7 255 0.5 10 
 
Another resin considered for the polishing step was the CIM multus 
Diethyl Amino Ethyl (DEAE)-1 monolithic column (BIA Separation). This 
resin is a weak anion exchanger with a similar binding characteristics of strong 
cation exchanger. Since information on interaction between the protein of 
interest and anion exchangers was available from platform n° 2, the peak eluted 
from Nuvia Q, containing the 13 kDa protein, was diluted twenty-fold with 0.1 
M Tris-HCl pH 10.5 and loaded on the column. The same elution gradient 
described in paragraph 3.3.6 was performed. Another alternative for the 
polishing step was the hydrophobic Phenyl Sepharose HP resin (GE). Before 
loading the sample on the column a stability test was performed as described 
in paragraph 3.3.3. In this case the variables considered were the type of salt 
used (NaCl or ammonium sulfate) for the salting out and its concentrations 
(range 0 to 2 M). NaCl and ammonium sulfate were screened with a linear 
model L18 with three levels. The three salt concentrations tested by the model 
were 0, 1 and 2 M with three replicates. 
The fraction containing the POI eluted from Nuvia Q was loaded on the 
Phenyl Sepharose HP after the addition of 1 M of ammonium sulfate. The resin 
was equilibrated with 50 mM phosphate buffer pH 8, 1 M ammonium sulfate 
and the elution buffer was the WFI. Initially, the elution was performed by a 
gradient of 10 CV from 1 M to 0 M of ammonium sulfate, subsequently, after 
the SDS-PAGE and WB analysis, the elution was optimized by a three step 
elution at the conductivity of 36, 20 and 0.2 mS/cm The peaks eluted were 
analyzed in SDS-PAGE, dot blot analysis, HCPs, rDNA, total and POI content.  
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3.3.8 Analytical methods 
3.3.8.1 SDS-PAGE and Semi-quantitative Western blot (WB) 
The protein samples were diluted with 5× of Laemmli buffer containing 
2-mercaptoethanol and incubated at 95 °C for 5 minutes. The samples were 
loaded in a 4-15% (for the 340 kDa protein study) or 4-20% (for the 13 kDa 
protein study) polyacrylamide gel (TGX Bio-Rad) and the electrophoresis was 
performed applying 200 V. For SDS-PAGE staining biosafe coomassie blue 
brilliant G-250 (Bio-Rad) and silverQuest Silver staining kit (Life 
technologies) were used. For WB the proteins were then transferred to a 
nitrocellulose membrane with Transblot Turbo instrument (Bio-Rad) applying 
2.5 A, 25 V for three minutes. The membrane was blocked for 30 minutes with 
5% (w/v) of milk in Tris Buffer Saline (TBS)-Tween 20 and incubated for 2 
hour with the primary antibody against 340 kDa protein (diluted 1/6000 in 
milk 1% (w/v)) or against 13 kDa protein protein (diluted 1/200 in BSA 1% 
(w/v)) and finally incubated for 1 hour with an anti-rabbit secondary 
polyclonal antibody Horseradish Peroxidase conjugated (HRP) diluted 1/4000 
in milk 1% (w/v). The membrane was developed with 4-chloro-1-naphthol and 
then analyzed with the software Image J. This software, used for the semi-
quantitative WB, allows to plot the bidimensional profile of the proteins area 
selected on the developed membrane. These areas can be compared and 
eventually quantified with the areas of a standard curve. 
 
3.3.8.2 Dot blot analysis 
A volume of 3 µL of the samples were spotted on a nitrocellulose 
membrane (GE) that was subsequently blocked for 30 minutes with 5% (w/v) 
of milk in TBS-tween 20 and incubated for 2 hour with the primary antibody 
and finally incubated for 1 hour with an anti-rabbit secondary polyclonal 
antibody HRP conjugated diluted 1/4000 in milk 1% (w/v). The membrane 
was developed with 4-chloro-1-naphthol. 
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3.3.8.3 Quantification of the protein of interest with Enzyme-
Linked ImmunoSorbent Assay (ELISA) sandwich test 
This assay consist in a commercially available quantitative sandwich 
enzyme immunoassay. A monoclonal antibody, used as “capture antibody” 
specific for the protein of interest, is coated onto a microplate. Plates are 
washed, and standards and samples are added to the wells: the protein of 
interest is bound by the immobilized antibody. After washing away any 
unbound substances, an enzyme-linked HRP conjugated specific for the 
protein of interest is added to the wells. Following a washing step to remove 
any unbound conjugate, a TetraMethyl Benzidine (TMB) substrate solution is 
added to the wells and color develops in proportion to the amount of the 
protein of interest. The color development is stopped and the intensity of the 
color is measured at 450 nm. 
3.3.8.4 Total proteins quantification 
For the optimization of the 340 kDa and 13 kDa production process, the 
total protein content was determined by Bradford protein assay (Bio-Rad) and 
BCA kit (Sigma) respectively. The quantifications were performed following 
the manufacturer’s instructions and using an affinity purified 340 kDa protein 
as standard and lysozyme for the 13 kDa protein. In the case of pure samples, 
the determination of the 340 kDa protein content was determined by 
absorbance readings at 280 nm using an Abs0.1% coefficient of 1.5 or 1.6 for 
the 350 or the 13 kDa protein (43). 
 
3.3.8.5 HCPs quantification 
The quantification of the HCPs was performed with the HCP ELISA kit 
(Cygnus) which allows the quantification of host proteins in samples. The kits 
used in this work were PER.C6 and E. coli HCP ELISA kit. Samples 
containing cell HCPs are incubated simultaneously with a HRP enzyme 
labeled anti-PER.C6 or E. coli cell antibody (goat polyclonal) in microtiter 
strips coated with an affinity purified capture anti-PER.C6 or E. coli cell 
antibody. The immunological reaction results in the formation of a sandwich 
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complex of solid phase antibody-HCP-enzyme labeled antibody. The 
microtiter strips are washed to remove any unbound reactant. The substrate, 
TMB is then reacted. The amount of hydrolyzed substrate is read on a 
microtiter plate reader and is directly proportional to the concentration of cell 
line HCPs present. 
 
3.3.8.6 Size exclusion chromatography (SEC) 
The SEC analysis was used to evaluate the composition of the HA eluates 
containing the 340 kDa protein. The analysis was performed on a Superose 6 
10/300 GL Tricorn column (GE) equilibrated on the ÄKTA purifier with 
degassed Dulbecco Phosphate Buffer (DPBS) (Lonza). 100 µl of samples were 
loaded and eluted using a linear flow rate of 40 cm/h. The chromatographic 
profile was monitored at the wavelengths of 280 and 260 nm in order to detect 
the profile of the protein of interest, aggregates and the content of DNA. 
 
3.3.8.7 Quantitative Polymerase Chain Reaction (qPCR) 
The extraction of residual cell DNA from the samples was performed 
using the PrepSEQ® rDNA Sample Preparation Kit (Applied Biosystems) 
according to the manufacturer’s instructions. The residual DNA quantification 
was performed by real-time PCR using the commercially available kit 
resDNASEQ® Human Residual DNA Quantitation Kit for the protein 
produced in PER.C6 cell line and resDNASEQ® E. coli Residual DNA 
Quantitation Kit (Applied Biosystems).  The assay was performed according 
to the instructions provided by the manufacturer and all the data were obtained 
using the 7500 fast real time PCR system instrument (Applied Biosystems). 
 
3.3.8.8 Bioactivity test of the 13 kDa protein: Rat C6 proliferation 
assay 
Before the assay, Rat C6 cells were cultured for 1 week in DMEM 
(Dulbecco’s Modified Eagle Medium) containing 2% (v/v) glutamine (Sigma) 
0.2 % v/v cholesterol (Gibco), 0.6 % (v/v) 2-mercaptoethanol (Sigma), 0.2 % 
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(v/v) insulin-transferrin (Gibco) and 1% or 10% (v/v) Fetal Bovine Serum 
(FBS) (SAFC) in humidified atmosphere with 5% CO2. Subsequently 2000 
cells cultured in 1% FBS at the concentration of 15 × 103 cells/mL were plated 
in each well of a 96 well plate. The cells were exposed to the 13 kDa 
recombinant protein (concentration range: 0.1 to 30 µg/mL) and incubated for 
72 hours. As positive control a commercial 13 kDa protein was used in the 
same concentration range of the purified protein and, as negative control, 1% 
FBS cells without the addition of the POI was used. 
After the incubation time, cells amount was quantified using the ViaLight Plus 
cell proliferation cytoxicity bioassay (Lonza) following the manufacturer’s 
instruction. 
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4. Results 
 
4.1 Development and optimization of the production process 
of a 340 kDa human protein by HTPD techniques 
4.1.1 Background of the process development: protein ID 
The aim of the first part of this work was the optimization of the 
production process of a 340 kDa human protein expressed in response to pro-
inflammatory signals. This molecule is a multimeric protein composed by eight 
identical subunits stabilized by interchain disulfide bonds able to stabilize four 
protein subunit in tetrameric arrangement and to link the tetramers into 
octamers. Each monomer is made of a specific sequence of 381 amino acids 
with an overall molecular mass of 40 kDa. In particular, the symmetric 
disulfide bonds are located among five cysteine residues located in position 
47, 49, 103, 317 and 318 of the primary sequence. The octamer is organized in 
two opposite oriented tetramer link to each other by the interchain bonds 317-
317 and 318-318 between the C-terminal of opposite oriented subunits.  
SDS-PAGE analysis under reducing conditions shows how the monomer 
deviate from the predicted Molecular Weight (MW) of about 3-4 kDa and this 
discrepancy is due to glycosylation (Figure 12). Using the server NetNGlyc 
1.0 (44), one glycosylation site can be predicted on asparagine 220 of the 
protein monomer, hence, the fully structured protein has eight glycosylation 
sites with fucosylated and sialyted complex-type sugars. These complex post- 
translactional modifications require the expression of this protein in a host cell 
able to ensure a glycosylation pattern coherent to the native one. For this reason 
the expression of the protein was performed in the PER.C6 cell line derived 
from primary culture of human fetal retinoblasts immortalized upon 
transfection with an E1 minigene of adenovirus type 5. 
The generation of PER.C6 was performed in compliance with Good 
Laboratory Practice (GLP) and has been extensively documented and the cell 
banks meet all pertinent US and EEC regulatory requirements. Moreover, 
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PER.C6 cells can be grown in suspension to high cell densities (up to 107 
cells/mL) in serum-free medium and without the aid of any solid support (45).  
 
 
Figure 12: SDS-PAGE and WB of the 340 kDa protein under reducing conditions 
Using the software CLC Main workbench (Qiagen) and the 
bioinformatics tool Protparam (Expasy), biochemical properties and 
information can be identified starting from the amino acid sequence. Table XII 
resumes the parameters of the 340 kDa protein monomer described in this part 
of the work. 
 
Table XII: Biochemical characteristics of the 340 kDa protein monomer 
Length 381 aa 
Weight 40.121 kDa 
Isoelectric point 5.11 
Aliphatic index 85 
Half-life: aa N-terminal  
glutamic acid 
1 hour 
Mammals 
30 min 
yeast 
>10 hours 
E. coli 
Extinction coefficient 
   at 280 nm 
Non reduced cysteines 
60710 mM-1cm-1 
Reduced cysteines 
60170 mM-1cm-1 
Extinction coefficient 
 absorption at 280 nm 
0.1% (=1g/L) 
Non reduced cysteines 
1.513 
Reduced cysteines 
1.500 
Secondary structure 
number 
Alpha helix: 8 Beta strand: 18 
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Figure 13a shows the plot of charge as a function of pH. The protein in its 
zwitterionic form has a neutral charge: its isoelectric point corresponds to 5.1. 
A hydrophilicity/hydrophobicity plot is shown in Figure 13b: the plot has 
amino acids sequence of a protein on its x-axis, and degree of hydrophobicity 
and hydrophilicity on its y-axis. It is useful to characterize or identify possible 
structure or domains of a protein. There is a number of methods to measure the 
degree of interaction of polar solvents such as water with specific amino acids. 
For instance, the Kyte-Doolittle scale gives information about the protein 
structure. For instance, if a stretch of about 20 amino acids shows positive for 
hydrophobicity, these amino acids may be part of alpha-helix spanning across 
a lipid bilayer; on the converse, amino acids with high hydrophilicity indicate 
that these residues are in contact with solvent, and that they are therefore likely 
to reside on the outer surface of the protein (46). The 340 kDa-protein 
monomer shows both hydrophobic and hydrophilic regions. This information 
was taken into consideration for the process development design. 
a)                                                     b) 
 
Figure 13: a) plot of charge as a function of pH, b) Kyte-Doolittle plot 
 
4.1.2 Production of the recombinant protein 
The production process of the protein of interest was performed starting 
from the cell bank expansion in flasks until the cell concentration reached 10-
20×106 cell/mL in order to inoculate a 5 L working volume bag. The cell bank 
expansion lasted about 7-8 days. The viable cell count during the flask 
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expansion was always maintained above 90%. The 5 L bag was inoculated at 
a VCC of 0.5×106 cells/mL and, during the growth, feed medium was added 
depending on the glucose concentration in order to avoid levels below 3 g/L. 
The duration of this phase was of 6-7 days with a final VCC between 8.5 and 
13.7106 cells/mL whereas the final culture viability was within the 82-95% 
range. These results are shown in Figure 14a where the viability and VCC of 
growth curves obtained from three different 5 L cultures are shown.                                                                                                                         
 
 a) 
 
 
 
 
 
                                       
b) 
 
 
 
 
Figure 14: a) Growth curves of three cultures at the 5 L scale. b) Growth curves of the 
25 L scale. VCC of each time point is represented in green whereas the viability is 
represented in red. The green and red lines correspond to the mean values 
The 100 L production campaign necessary for the production of about 5 
g of the 340 kDa protein from PER.C6 cells, was performed with four parallel 
bioreactors of 25 L. Cells were inoculated at a VCC of 0.5×106 cells/mL and 
grown with daily monitoring for glucose consumption, pH (Figure 15a-c) and 
VCC (Figure 14b). A clear pH drift could be observed along the duration of 
the culture with a final value at harvest of 6.3 (Figure 15c). The initial glucose 
consumption was 0.6-0.5 mg/106 cells/day starting from the second day to the 
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fourth day of culture and remained constant at 0.2 mg/106 cells/day for the 
remaining period (Figure 15b). The cultures were stopped when viability was 
below 70%. As shown in Figure 15d the average of the maximum VCC 
obtained for the four 25 L fermentations was 14.8×106 cells/mL and 11.7×106 
at harvest. The average protein of interest production in PER.C6 cell line was 
104 mg/L (Figure 15e). 
 
 
                                      
 
 
 
                             
                           
 
 
 
 
 
Figure 15: a) Glucose levels and b) 
glucose consumption of the 25 L scale 
cell culture. Each dot represents the 
glucose level fermentation broths. The 
dark blue and black lines correspond to 
the average value. c) pH values: each 
reading is represented by a dot whereas 
the line corresponds to the mean values 
at each time point. d) Summary of the 
VCC (maximum and at the harvest) for 
the 25 L cultures. e) 340 kDa-protein 
production level obtained from the 4 ×     
25 L production campaign 
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4.1.3 Limits of the non-optimized downstream process and 
proposals for new improvements  
After the upstream phase, the feedstock of the PER.C6 culture needed to 
be processed in order to purify the protein of interest. In the non-optimized 
process the harvest of a 25 L cell supernatant was achieved by high-speed 
centrifugation but the scale-up of this step was a limit. Continuous 
centrifugation could be the key of this bottleneck but the choice is mainly a 
matter of costs: actually, this approach is the preferred clarification method for 
large scale process. The choice of a clarification method depends on equipment 
availability, the cell culture process (including the cell line and the cell viability 
at time of harvest), process economics and scale of the process. For relatively 
medium-high scale processes, up to 4000 L, depth filtration may be a more 
efficient method of clarification. Depth filtration use is also essential in a full-
scale industrial process after an eventual continuous centrifugation. In this 
work a depth filtration step and its sizing was studied and tested in order to 
introduce this technology in the process. 
The core of the downstream process is chromatography. The standard 
process was characterized by three chromatographic steps corresponding to 
capture, intermediate and polishing step (Figure 16). The capture step was 
performed by loading the feedstock on the Q Sepharose FF equilibrated with 
50 mM Tris-HCl, 400 mM NaCl pH 7 and eluting the fraction containing the 
protein of interest with 50 mM Tris-HCl, 650 mM NaCl pH 7. The latter 
fraction was loaded on the hydroxyapatite conditioned with 10 mM sodium 
phosphate buffer pH 7 and the protein of interest was eluted with 350 mM 
sodium phosphate buffer pH 7. The last purification step was achieved by HIC 
using the Phenyl Sepharose FF resin. After the addition of NaCl, in order to 
reach the concentration of 2 M, the sample was loaded on column and eluted 
with WFI. The last step of the downstream phase was the concentration and 
diafiltration of the protein carried out by TFF on a 100 kDa MWCO membrane.  
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Figure 16: Non-optimized downstream process scheme of the 340 kDa-protein 
A challenging aim of the purification steps is the reduction of 
contaminants such as HCPs, rDNA, aggregates and endotoxins. Table XIII 
resumes all the downstream steps and the contaminant content (where 
available) of the non-optimized process, pointing up the impact of the single 
steps on impurities reduction expressed by Log reduction.  
 
Table XIII: Downstream steps and contaminants contents of the non-optimized process 
STEP 
STEP 
YIELD 
HCPs 
Log red 
HCPs ppm 
DNA 
Log red 
DNA 
ppm 
AEX 100 % 2.6±0.05 8000 - - 
HA 70% 0.3±0.05 4800 - - 
HIC 55% 0.4±0.10 2600 - - 
TFF 95% 0.3±0.05 900 - - 
 
This purification approach fulfilled the endotoxin requirement of 10 
EU/mg because all the process was performed in an endotoxin-free mode using 
disposable and sanitized equipment, but the others impurities levels were 
outside specifications. In particular HCPs were not in the range of 1-100 ppm 
and the content of rDNA was above the limit of 10 ng per dose of 
biotechnological drug as described by guidelines on the quality, safety, and 
efficacy of biotherapeutic protein products prepared by recombinant DNA 
technology (World Health Organization (WHO)) (47). 
In this PhD work the process was further optimized in order to introduce 
a fully compliant GMP process. First, the three chromatographic steps were 
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optimized in terms of HCPs and rDNA reduction by screening and DoE 
approaches. In particular in the capture and polishing steps, these studies were 
used in order to introduce washing steps able to decrease impurities content. 
The QbD, achieved by the DoE approaches, was also used in the intermediate 
step on hydroxyapatite to reduce the concentration of phosphate in elution 
buffer preventing the co-elution of the POI and the rDNA. 
Further strategy followed to reduce contaminants was the introduction of 
a membrane chromatographic step. Membrane chromatography has 
demonstrated unparalleled performance for flow-through applications. For this 
reason, a screening of three chromatographic membranes was performed in 
order to adapt this technology for trace contaminant removal and virus 
clearance applications. Anion exchange chromatography is most widely used 
for this unit operation and has been validated for use since 2001 (48). Finally, 
further aim was the introduction of viral reduction steps achieved by thermal 
inactivation and filtration, in order to satisfy ICH Q5A guidelines. In 
particular, three different virus removal filter were tested and sized in order to 
identify the best in terms of performances for the implementation in the full 
scale process. 
 
4.1.4 New disposable pilot scale depth filtration technologies  
The protein of interest, expressed by PER.C6 cells, is secreted in the 
culture medium. At small to medium scales, single-use technology offers 
significant advantages over traditional reusable (e.g., stainless steel) 
manufacturing technology with regard to flexibility, cost of goods, 
implementation timelines, and maintenance. However, process design based 
on disposables does create new challenges. For processes based entirely on 
disposables, the disc-stack centrifuge needs to be replaced by filtration alone. 
In the first step, the cellulose Millistak+ POD D0HC and Supracap 100 filter, 
connected in series with a PES 0.22 µm filter for the final clarification, were 
tested. For the laboratory-scale screening 10 L of high density fed batch 
PER.C6 cultivation broth were used. Harvest was performed after 14 days 
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with a viability of 94%. During the filtration, a constant flux of 100 L/m2/h 
was applied. The filter capacity, turbidity, yield and the pressure were 
monitored during the process. Figure 17 shows Millistak+ POD and Supracap 
100 capacity (L/m2) plotted against pressure (bar). The maximum filter 
capacity was determined at the pressure of 1 bar. At low differential pressure, 
the filters show exponential curve typical of a filtration process with constant 
flow. After processing 6 L of broth the MilliStak+ POD filtrate throughput 
showed turbidity and the 0.22 µm filter was clogged. This filter processed 
about 6 L reaching a maximum capacity of about 110 L/m2 at 0.7 bar. The 
capacity of Supracap 100 was about 100 L/m2 at 1 bar without turbidity.  
The scale-up was performed processing 100 L of the same PER.C6 
culture using two 1 m2 Stax filters considering a capacity of 50 L/ m2 (safety 
factor = 2). As showed in Figure 17, the Supracap results were confirmed with 
Stax system, in fact, with 2 m2 of superficial area, the maximum capacity at 1 
bar was not reached. The results obtained show that the Millipore Millistak+ 
POD filter was able to process about 110 L/m2 but turbidity breakthrough at 
pressure below 1 bar was observed and consequently this filter was not 
considered for the scale-up. 1 m2 Stax filter was necessary to process 50 L of 
PER.C6 culture avoiding turbidity and clogging of 0.22 µm filter. 
 
 
Figure 17: Comparison of the pressure/capacity relation for Millistak+ POD D0HC 
Supracap 100 and Stax filter. The red dot represents turbidity threshold of POD 
system 
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4.1.5 Determination of the Q Sepharose, HA and Phenyl Sepharose 
binding capacity 
The binding capacity corresponds to the quantity of a specified molecule 
such as protein, DNA and virus that can be bound by a resin. It is common 
practice in chromatography to express the binding capacity in milligrams of 
proteins per milliliters of resin. The dynamic binding capacity may be 
determined from breakthrough curves. These are obtained by measuring the 
outlet protein concentration during continuous feeding of the equilibrated 
chromatographic medium. Total breakthrough is obtained when the outlet 
protein concentration equals the feed concentration. The dynamic binding 
capacity represent the quantity of protein bound to the resin under the operated 
flow conditions. It is commonly measured as the quantity of protein that has 
been retained by resin at 5% breakthrough. 
As described in paragraph 3.2.3, 12 fractions of 1 mL were collected for 
each binding test and then analyzed by semi-quantitative WB in order to 
determine the concentration of the protein.  
Appreciable intensity signals of the protein were identified after loading 
1 mg for Q Sepharose and Phenyl Sepharose or 2 mg for HA (Figure 18). The 
binding capacity determined at 5% breakthrough at the flow rate of 80 cm/h 
were 1 mg/mL for Q Sepharose and Phenyl Sepharose while 2 mg/mL for HA. 
 
                                                                                                
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Relationship between percent breakthrough determined by semi-
quantitative WB and protein loaded on the three resins. The binding capacity were 1 
mg/mL for Q Sepharose and Phenyl Sepharose while 2 mg/mL for HA 
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4.1.6 Set-up of the HA purification step with HTPD 
In the non-optimized process the fraction eluted from the Q Sepharose 
resin was loaded on HA. Subsequently the resin was washed with 10 mM 
sodium phosphate buffer pH 7 and the protein of interest was eluted with 350 
mM of sodium phosphate buffer pH 7 while most of HCPs are eluted at 500 
mM of the same buffer. Figure 19 represent the SEC chromatographic profile 
of the fraction eluted at 350 mM of sodium phosphate buffer. With this 
approach, the protein of interest co-elutes with contaminant host’s DNA. The 
first peak contains the protein of interest while the peaks at higher retention 
times contains low molecular weight DNA fragments. The absorbance ratio 
260/280 nm indicates the presence of residual DNA in the late eluting 
fractions (> 16 mL). 
 
 
Figure 19: SEC of non-optimized hydroxyapatite eluate. The analysis was performed 
on a Superose 6 column and monitored following the absorbance at 260 nm and 280 
nm 
In order to reduce the contaminant DNA an HTPD approach was used as 
described in paragraph 3.2.4. The 28 elution conditions were analyzed by 
ELISA, HCPs test and quantified for rDNA. The results obtained allowed 
MODDE to propose a model to explain the protein elution behavior. The 
predicted contour graph is shown in Figure 20. The model had a R2 of 0.795 
and a Q2 of 0.72, hence, was able to fit the data and was used for elution 
prediction. The results showed how there were not significant differences 
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between the three different elution buffers pH, in fact, this coefficient was not 
significant in the model. Furthermore, washing the resin with 50 mM 
phosphate buffer the yield of the protein of interest was about 70-80% while 
at lower concentrations the yield decreased up to 20%. 
 
Figure 20: The contour graph resumes the yields of HTPD work. As shown in the 
figure there are not differences in terms of yield varying the pH and the maximum 
of recovery (about 70%) is reached at 50 mM of sodium phosphate 
High and low molecular weight DNA strongly bound to HA at low 
phosphate buffer concentrations and approximatively a 100 mM solution was 
necessary for the elution. This observation and the results of the HTPD 
approach allowed to redefine the chromatographic step on HA. Sodium 
phosphate buffer at pH 7 was added from a 500 mM stock to Q Sepharose 
eluate in order to reach the concentration of 50 mM. The eluate was loaded on 
the resin and the protein of interest was collected in the FT. DNA and HCPs 
were eluted with 500 mM of sodium phosphate buffer pH 7. Figure 21 shows 
the SEC profile of the redefined chromatographic step. The profile shows 
highly reduced DNA peaks compared to the SEC of the non-optimized 
process. The yield of the protein of interest was about 70%, the HCPs Log 
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reduction step was about 0.6 and the Log reduction step of DNA by qPCR was 
3.6. 
Figure 21: SEC analysis of the FT fraction of optimized HA step  
 
4.1.7 HCPs and rDNA reduction approaches introduced in the 
downstream process 
Process-related impurities are cell components such as HCPs or DNA, 
chemical additives, residual media components or leachables. HCPs are a 
complex mixture of proteins significantly differing from each other in their 
molecular mass, isoelectric point, hydrophobicity and structure. These 
properties present a challenge for product purification due to the modification 
in level, composition and property distribution during a single fermentation 
process. In the non-optimized downstream process the capture step on Q 
Sepharose FF allowed to reach an amount of 8000 ppm and a Log reduction 
of 2.6±0.05 of HCPs. As described in paragraph 3.2.5 some different 
components were tested in Q Sepharose washing buffer in order to evaluate 
their capability to reduce HCPs-anion exchanger or HCPs-protein of interest 
interactions. Figure 22 resumes the results obtained from this screening. 
-5
5
15
25
35
5 10 15 20 25
m
A
u
mL
Abs 280 nm Abs 260 nm
 80 
 
 
 
Figure 22: Log reductions and yields obtained from the use of different concentrations 
of components applied in washing steps 
The results show that the best condition in terms of yield and Log 
reduction was obtained with the introduction of a washing step with 50 mM 
arginine achieving a Log reduction of 2.75±0.02 and about a full recovery of 
the protein of interest. Higher arginine concentration was able to reduce 
contaminant but yield was dramatically reduced because of the capability of 
arginine to weaken interaction between ion exchangers and proteins. On the 
other hand, no significant reductions of HCPs using different concentrations 
of MgCl2, glycerol, ethanol or polysorbate 20 were observed.  
 
Many studies demonstrated that arginine weakens hydrophobic 
interactions and facilitates elution of bound proteins from Phenyl Sepharose 
during decrease of salt concentration. In addition, inclusion of arginine in the 
loading sample increased the recovery of the total protein and decreased the 
aggregation during ion exchange chromatography (IEX) (49). In this work a 
screening of different concentrations of arginine and NaCl included in sample 
and loading buffer of HIC was performed in order to evaluate the possibility 
to reduce NaCl increasing arginine and to identify the best arginine 
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concentration able to eventually reduce HCPs content. Contours graphs in 
Figure 23 resumes the results obtained. 
 
 
a) 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
                                     
 
                               c) 
                            
 
 
 
                                                                                 
         
Figure 23: a) Contour graphs for Log reductions and yields obtained from the use 
of different concentrations of excipients applied in HIC screening. b) Summary of 
fit of the two response model. c) Coefficients plots of the two models 
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In the non-optimized downstream process the chromatographic step on 
Phenyl Sepharose FF allowed to obtain a yield of 55% and a Log reduction of 
0.4±0.1 of HCPs. Figure 23 shows that below the concentration of 1 M NaCl 
the recovery of the protein of interest ranged from 35 to 20%, hence, these 
values were too low to allow the protein binding on the resin. Similarly, the 
recovery yields were about 20-30% increasing the amount of arginine at these 
NaCl concentrations. Best conditions were obtained at 2 M NaCl with the 
addition of 50 mM arginine where the yield reached values of 70% and a Log 
reduction of 0.6 was the best. The yields and Log reductions slowly decreased 
with increasing arginine concentration in the samples containing 2 M NaCl. 
This could be probably due to the altered interactions between the protein of 
interest or HCPs with the resin in presence of high concentrations of the two 
salts. Both the models proposed to describe the cause-and-effect relationship 
for POI yields and HCPs Log reduction were statistically relevant, hence, they 
were considered valid; moreover, the models had a good fit and a good 
capacity to predict future experiments as shown by the values obtained for R2 
and Q2 (Figure 23b). Figure 23c resumes the coefficients plots for POI yields 
and HCPs Log reduction. In both the responses considered, increasing NaCl 
concentration significantly favored the protein of interest binding and 
reduction in HCPs. Arginine concentration was able to explain the POI yield 
only when considered as a quadratic effect term turning the linear regression 
into a curve. In the HCPs Log reduction model the increase of this amino acid 
boosted the HCPs interaction with the resin, moreover, the interaction between 
NaCl and arginine was significative: this interaction was evident only when 
one of the two salts increased and the other decreased (or vice versa).  
A relatively new development in membrane technology is the membrane 
chromatography. These are symmetric microfiltration membranes 
functionalized with specific ligands attached directly to the convective 
membrane pores. Diffusive pores are eliminated, mass transfer of 
biomolecules depends on convection and the binding capacity is largely 
independent on flow rates. Significant advances have recently been made in 
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developing high permeability and high capacity sterile filters by application of 
composite membranes. Membrane adsorbers are used for polishing 
applications aimed to remove contaminants. Viruses, endotoxins, DNA, HCPs 
and leaches bind to the membrane at neutral to slightly basic pH and low 
conductivity values. Additional developments investigate the possibility to 
apply membrane adsorbers in capture and purification of large biomolecules 
and focus on new designs of structures for bind-and-eluate processes. In this 
work three different chromatographic membrane were tested in order to 
introduce a polishing step in the downstream process. The Q Sepharose FF 
eluate had a concentration of 650 mM NaCl and, at this salt concentration, the 
tests were performed in negative mode where the protein of interest is collected 
in the FT and all the undesired contaminants are trapped and bound to the 
membrane. Table XIV resumes the results obtained in terms of yields, HCPs 
and DNA reduction. 
 
Table XIV: Yield and reduction of contaminants obtained in membrane 
chromatography screening tests 
 
DNA Log 
red 
HCP Log 
red 
Yield 
MUSTANG Q 0.6±0.1 0.30±0.05 97% 
CHROMASORB 0.1±0.1 0.17±0.05 69% 
MUSTANG S 0 0.01±0.05 84% 
 
Mustang Q had the best performance in terms of DNA reduction (0.6±0.1) 
compared with other membranes, coupled to a very high recovery. On the other 
hand, the HCPs reduction was limited with the three systems used. 
Nevertheless, Mustang Q performed better than Chromasorb and Mustang S. 
Based on these results, Mustang Q was introduced in the scale-up of 
downstream process.  
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4.1.8 Feasibility study of viral clearance by thermal inactivation 
and NFF 
Biopharmaceutical products, such as monoclonal antibodies, 
recombinant proteins, vaccines, blood derivatives and animal products carry 
an inherent risk of transmitting infectious viruses due to the source material 
used, manufacturing processes, and routes of administration. All of the 
regulatory guidelines emphasize that each viral validation study should be 
reviewed on a case-by-case basis and that Log reduction factors obtained 
should be viewed under experimental limitations and product-specific risk 
factors. A manufacturing process for the production of biopharmaceuticals 
should incorporate at least two distinct robust virus clearance steps, with at 
least one step effective on non-enveloped viruses. Robust steps are those able 
to clear a wide range of viruses and are not influenced by process variables 
(pH, protein concentrations, buffers, temperatures etc.). Scaling-down the 
process steps to be evaluated is a prerequisite to performing the actual spiking 
experiments, as it would be impractical to use the actual production scale for 
the viral clearance study due to the volumes of virus needed. In this work, two 
steps for virus clearance were evaluated. First, the fraction from the HIC step 
at the concentration of 0.4 mg/mL was processed for thermal viral inactivation 
at 60±2 °C for 4.0±0.1 hours under continuous stirring. The protein yield after 
the treatment was 97% and the step HCPs Log reduction was 0.2. The SEC 
profile before and after the treatment was assessed and the profiles are 
reported in Figure 24. 
a)                                                                                                          b) 
 
Figure 24: SEC profile of HIC eluates before (a) and after (b) thermal inactivation 
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The SEC profiles show no significant changes in dimer, trimer or 
aggregates before the main octameric protein peak. These results show that 
the heat-treatment can be easily introduced in the viral clearance step because 
it has no significant effect on protein structure and yield. As described in 
paragraph 3.2.7, after the thermal inactivation step the feasibility of virus 
clearance by a normal flow filtration through the screening of different 20 nm 
filters was evaluated. 
In order to save the highest amount of product all trials were run with 50 
mL of product. Collected data were placed in a graph by plotting the loading 
versus the flow decay (Figure 25). 
 
Figure 25: Viral clearance by 20 nm filtration. Flow decay vs loading are plotted for 
the six experiments 
The red line represents the limit of the flow decay used for sizing 
calculation (flow at 25% of the initial means 75% of flow decay). The product 
loading (filter capacity) with dedicated prefilters is meaningfully higher than 
Virus filter (Vpro) alone. The performance given by the SHR filter is able to 
increase the Vpro capacity more than 50% but the Vshield H31 prefilter 
showed the best performance. DV20 and SV4 without any 0.1 µm filter were 
stopped at about 60 L/m2 of loading and their flow decay trends were less 
pronounced that other filters. In particular this effect is more evident for DV20 
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filter. The results obtained are summarized in table (Table XV), also including 
the sizing for 50 L process.  
 
Table XV: Summary table of the filtrations viral step clearance results   
Device Prefilter 
Vmax 
(L/m2) 
 V75 
(L/m2) 
Pressure  
    (bar) 
   Trial 
 Loading 
   (L/m2) 
Initial 
 flux 
(LMH) 
Average 
   flux 
  (LMH) 
  % 
 yield 
Sizing 
  50 L 
  (m2) 
Safety  
factor 
Vpro   None  65.2    32       2    47.7  348    142    90     2.2   1.4 
Vpro  V shield 165.1    83       2    60.3  387    182    87     1.1   1.8 
Vpro     SHR 165.4    83       2    65.4  406    196    81     1.1   1.8 
Vpro    H31  227   114       2    86.8  406    209    81     1.1   2.5 
SV4   None  450   225       2    52.1  33.7     30    94       1   1.7 
DV20   None  868   434       2    59.3  24.3     23    96       1   1.6 
 
4.1.9 Scale-up of the recombinant protein production process 
As described in paragraph 3.2.8 and 3.2.9, a scale-up to 25 L and 100 L of 
the downstream process was performed in order to assess the reproducibility of 
yields and contaminants reduction. The entire production process together with 
the viral inactivation and reduction steps is schematically represented in Figure 
26.  
 
 
Figure 26: Schematic representation of the 340 kDa-protein production process 
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The cell culture was harvested by depth filtration followed by sterile 
filtration and was subsequently loaded on the Q Sepharose Fast Flow anion-
exchanger equilibrated with 50 mM Tris-HCl, 400 mM NaCl, pH 7.0 taking 
advantage of the low isoelectric point of the protein of interest (pI 5.1). The 
elution was achieved by increasing the ionic strength with 50 mM Tris-HCl, 
650 mM NaCl, pH 7.0 after a washing step with 50 mM Tris-HCl, 50 mM 
arginine pH 7.0 in order to reduce the HCPs and residual DNA content. The 
HCP content in the non-purified bulk was 100 mg/L and the average residual 
DNA content of 13 mg/L. With Q sepharose FF capture step the HCPs and 
DNA Log reduction were 2.8 and 1.7 respectively (Table XVI). 
The fraction eluted from the Q Sepharose step was processed on a 
Mustang Q XT membrane chromatography filter in order to further increase 
the DNA reduction (Table XVI). The FT from the Mustang Q step was 
adjusted to a concentration of 50 mM sodium phosphate and processed by 
chromatography on a Macroprep Hydroxyapatite column based on complex 
interactions of proteins with the positively charged C-sites (calcium ions), and 
negatively charged P-sites. The sample was loaded assuming a dynamic 
binding capacity of 2 mg/mL at a linear flow of 76 cm/h. The decrease in 
conductivity during the washing step induced a pH increase leading to the 
concomitant elution of protein of interest. This chromatographic step reached 
a POI yield of 73% with a HCPs Log reduction of 0.6 and a rDNA Log 
reduction of 3.5. 
The concentration of NaCl and arginine in the fraction of interest were 
adjusted to 2 M and 50 mM, respectively. The sample was then loaded on a 
Phenyl-Sepharose (high substitution) column. The addition of 2 M NaCl 
allows a complete binding of the protein of interest to the resin whereas the 
addition of 50 mM arginine reduce the interactions between the HCPs with the 
hydrophobic functional groups of the resin. The protein of interest was eluted 
with WFI in approximatively 1.7 CV at a protein concentration of 0.7 mg/mL. 
The eluted fraction represents 70% of the loaded protein of interest and with a 
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HCPs reduction of 0.5 Log. The final polishing of rDNA was achieved in this 
chromatographic step, obtaining a Log reduction of 0.2. The eluted fraction 
obtained from the HIC step was processed for viral thermal inactivation at 
60±2 °C for 4.0±0.1 hours under continuous stirring followed by 0.1 µm 
filtration and viral removal through filtration at 20 nm. The final product was 
concentrated to 2.6 mg protein/mL and formulated by tangential flow filtration 
on a 0.1 m2 PES cassette with a 100 kDa cut-off. The buffer exchange was 
performed against 7 buffer volumes of sterile filtered 10 mM sodium 
phosphate, 150 mM NaCl pH 7.0 at constant volume. The viral inactivation 
and removal steps together with the diafiltration, did not have significant effect 
in HCP reduction, in particular the Log reduction of these steps was 0.4. 
Regarding the clearance of rDNA Log reduction, the steps effective in rDNA 
removal were 0.1 µm filtration step and TFF with a Log reduction of 0.3 and 
0.7, respectively. A total recovery of the protein of interest was obtained in the 
viral inactivation step whereas the viral removal and diafiltration steps resulted 
in a yield of 94 and 95%, respectively. 
The yield of purified protein of interest at the end of the process was 41%, 
corresponding to approximately 43 mg of purified protein/L of cell culture. 
Regarding contaminant reduction, the concentration of HCPs/mg 340 kDa- 
protein in the final drug product was 147 ppm, with a cumulative Log reduction 
of 4.3, while residual DNA concentration at the end of the process was 0.06 
ng/mg protein of interest, with a Log reduction of 7. 
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Table XVI: Summary of the downstream process in terms of total and step yields, 
protein of interest production and contaminants reduction  
 
Purification step 
Vol 
(L) 
POI 
 (g/L) 
POI 
content 
(g) 
Step 
yield 
(%) 
Total 
yield 
(%) 
HCD 
(ng/mg) 
HCD  
(Log red) 
HCPs 
(ppm) 
HCPs 
(Log 
red) 
Non purified 
bulk 
100.00 0.104 10.4 - - 253846 - 930728 - 
IEX (Q-
Sepharose) 
9.60 1.08 10.4 100 100 5065 1.7 1626 2.8 
IEX (Mustang Q) 10.18 0.99 10.1 97 97 1310 0.6 1626 0.0 
HA (CHT-I) 2.14 3.46 7.4 73 71 0.57 3.5 688 0.6 
HIC (Phenyl 
Sepharose) 
6.48 0.77 5.0 68 48 0.53 0.2 335 0.5 
Viral clearance 
(heat inactivation) 
6.48 0.77 5.0 100 48 0.53 0.0 211 0.2 
Viral clearance 
(0.1 µm filtration) 
6.20 0.77 4.8 96 46 0.28 0.3 211 0.0 
Viral clearance 
(20 nm 
nanofiltration) 
7.00 0.64 4.5 94 43 0.28 0.0 163 0.1 
TFF 1.65 2.60 4.3 95 41 0.06 0.7 147 0.1 
 
4.2 Development of a systematic approach for the purification of a 
13 kDa human protein produced in E. coli 
4.2.1 Introduction  
Purification of recombinant proteins for therapeutics or analytical 
applications requires the use of several chromatographic steps in order to 
achieve a high degree of purity. A range of techniques is available such as 
anion and cation exchange chromatography, which can be carried out at 
different pHs and used at different steps, hydrophobic interaction 
chromatography, size exclusion chromatography and affinity chromatography. 
Until now it is virtually impossible to select separation and purification 
operations for proteins in a fully rational manner due to a lack of fundamental 
knowledge on the molecular properties of the materials to be separated and the 
lack of an efficient system to organize such information (50). 
For this reason, in the second part of my PhD project, the DoE and HTPD 
technology were used as a systematic approach for the optimization of the 
purification process of additional recombinant proteins. These two innovative 
techniques were used as a standardized “tool box” in order to introduce the 
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purification steps of a 13 kDa protein expressed in E. coli as inclusion bodies. 
The intention was to propose a comprehensive approach based on a step by 
step “decision tree” in order to point out a well-defined path in the purification 
and formulation of the protein of interest. As shown in the diagram reported in 
Figure 27 the approach starts when the information about the protein of interest 
and the contaminants in the feedstock are acquired. The information about the 
protein of interest are obtained from its sequence. In this case the theoretical 
biochemical characteristics of the protein can be gathered using for example 
the software CLC Main workbench or the Protparam tool. Regarding 
contaminants information, in particular the HCPs, a literature investigation is 
necessary in order to find the main biochemical properties of host proteins to 
address the subsequent purification steps.  
A first optional starting step of the approach consist in an initial 
assessment of the protein’s stability in the purification environment. A 
stability “tool box” based on a specific full factorial DoE is necessary to 
investigate the role of pH, ionic strength, excipients, incubation time, 
temperature and specific buffers on HCPs and POI stability. This assessment 
is more than ever essential in the last part of the process development where 
the drug product need to be formulated. 
After this analysis, the systematic approach goes on with the purification 
steps investigation. Initially, the choice of the purification path depends on the 
biochemical characteristics of the protein of interest. For instance, if the 
protein is engineered with a specific tag, the affinity purification could be the 
first choice for its purification. Otherwise, if a protein mixture is clearly 
defined in terms of molecular weight composition a SEC could be a good 
choice if the process volumes are modest and the purification step does not 
need to be scaled up. In all other cases IEX, mixed mode chromatography or 
HIC are considered the first option for the capture chromatography. Normally 
the capture step of the protein of interest relies on IEX which exploits the 
divergences between solution pH and pI of the proteins. In an industrial 
process development, the choice of the IEX as a first step of purification is 
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strongly suggested in order to implement the concept of the continuous 
downstream processing of biopharmaceuticals. A shift to continuous operation 
can improve productivity of a process and substantially reduce the footprint. 
Moreover continuous operations also allow robust purification of labile 
biomolecules and this approach can easily applied to chromatography (51). 
Hence, it is easy to figure an eluate from IEX step containing an adequate 
amount of a salt used to increase the ionic strength (i.e. NaCl), which is thus 
available to be directly loaded on a HIC resins needing of a high ionic strength 
in order to ensure the salting out effect. Therefore, the second DoE platform 
proposed for the capture set-up combines a matrices of different variables such 
as buffers pH, resin matrix and exchangers, ionic strength, in order to identify 
the best condition for the binding of the protein of interest by FT analysis. In 
this case, the third DoE “tool box” is presented by the set-up of a Response 
Surface Methodology (RSM) platform to establish the best elution condition 
for the protein of interest.  
Typically a chromatographic step like the capture requires a “bind and 
elute” mode, but, if the FT analysis reveals that a specific condition tested 
allows the binding of the contaminants but not of the protein of interest, the 
approach can be converted in a “flow through” mode for the purification step.   
This rational approach, proposed for the chromatographic capture step, 
with its DoE, can be conceptually applied in every chromatographic step as 
the intermediate and polishing steps.  
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Figure 27: Schematic representation of the “decision tree” for the development of a 
systematic purification approach 
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The protein chosen to test the mentioned approach is a 13.6 kDa protein 
expressed in E.coli as inclusion bodies and used in rescue of the retinal 
function in glaucoma. The 13.6 kDa mass is referred to its monomeric form 
but the biologically active structure is a homodimer of about 27 kDa. As 
mentioned for the 340 kDa protein, the software CLC Main workbench and 
the bioinformatics tool Protparam allowed to obtain the main biochemical 
properties from the amino acid sequence, see Table XVII. The protein of 
interest is a basic and highly hydrophobic protein. The purification 
development is complicated by these characteristics and the instability of the 
molecule in neutral, low ionic aqueous buffers. 
  
Table XVII: Biochemical characteristics of the 13 kDa protein monomer 
 
As described in the introduction of this chapter, also the information of 
the main E. coli HCPs are essential for the set-up of the approach. Some 
information about these contaminants were found in the literature (50-52).  
The protein, after the refolding, was solubilized in a buffer containing 0.1 
M Tris-HCl, 1 M arginine pH 9.5. In order to proceed with the protein 
purification, arginine must be removed due to its ability to modulate binding 
and elution in IEX and HIC chromatography (49). A dialysis/diafiltration step 
Length 120 aa 
Weight 13.6 kDa 
Isoelectric point 9.8 
Aliphatic index 62 
Half-life: aa N-terminal  
glutamic acid 
30 hours 
mammals 
>20 hours 
yeast 
>10 hours 
E. coli 
Extinction coefficient 
   at 280 nm 
Non reduced cysteines 
22550 mM-1cm-1 
Reduced cysteines 
22190 mM-1cm-1 
Extinction coefficient 
 absorption at 280 nm 
0.1% (=1g/L) 
Non reduced cysteines 
1.653 
Reduced cysteines 
1.627 
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was thus required. In order to maintain the same pH of the refolding buffer, 
four basic buffers were screened in order to identify the best in terms of total 
protein content and reduced amount of protein precipitate. The analyses 
performed, as described in the paragraph 3.3.2, were: total protein content, POI 
content and turbidity. The results are shown in Figure 28. The graph shows 
how the best conditions were obtained by decreasing arginine content with 
Tris-HCl pH 9.5: in this condition, the total protein reduction was about 30% 
and 90% of the remaining total protein content was composed by the POI. A 
drastic effect was achieved using the other buffers: the substitution of Tris with 
carbonate, glycine or phosphate caused a dramatic precipitation of the HCPs 
and the POI. The effect was significative using phosphate buffer where an 
additional negative effect on protein stability was caused by pH decrease up to 
pH 8. These results allowed to choose Tris-HCl buffer in order to reduce the 
amount of arginine in refolding buffer and to proceed in subsequent 
purification set-up without its interference. 
 
Figure 28: Screening of four different basic buffers in order to reduce arginine 
concentration from refolding buffer 
4.2.2 Platform set-up for protein stability testing (platform n°1) 
The first platform mentioned in the decision tree approach was the 
“protein stability test”. As described above, a step committed to investigating 
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the protein stability in the purification environment and eventually in the last 
step of protein formulation is essential in order to predict the protein behavior 
in terms of aggregation, precipitation, denaturation and loss of activity. 
Considering the first part of the downstream process, corresponding to the 
initial purification steps, some variables such as pH, ionic strength, 
temperature, time and the starting total protein concentration could affect 
protein stability. Table XVIII resumes the main factors of the platform. This 
table was compiled using the parameters requested in the upper part and 
subsequently all the data were inserted in MODDE software in order to 
propose the list of the full factorial experiment. 
 
Table XVIII: Summary of the main factors needed for the set-up of the stability testing  
 
In order to test how these factors can alter protein composition in 0.1 M 
Tris-HCl buffer used during the chromatographic steps, a DoE based on a 
fractional factorial V+ resolution was performed.  
The results obtained from the screening are shown in Figure 29. First, 
considering the fit plot histogram, the model of the ANOVA analysis showed 
very high values in terms of R2, Q2, model validity and reproducibility and this 
implies a good model. As a matter of fact, a high degree of response variation 
(R2 of 0.913) was explained by the model, it was highly predictive (Q2 of 0.813) 
and was also considered valid and highly reproducible. The coefficient plot 
shown in Figure 29b describes the main terms of the model and the interactions 
Ionic strength
Choose the type 
of salt (i.e. 
NaCl or 
(NH4)2SO4)
Define the 
concentration 
range
NaCl from 0 to 
1 M
pH
Choose the pH 
range (2 to 12)
Choose the acid 
or base to add 
(HCl, NaOH, 
CH3COOH 
etc.)
4 to 10.5 (HCl 
and NaOH)
Time
Choose  the 
incubation time 
(the variable 
must be 
quantitative 
multilevel)
0, 1 and 2 
hours
Temperature
Temperature 
range: from 2-8 
°C to R.T. (the 
variable must 
be quantitative 
multilevel)
2-8 °C and 
R.T.
Protein 
Concentration
Choose the 
concentration 
range)
From 0.75 to 
0.1 mg/mL
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able to improve it. A stability effect was observed increasing the pH but 
otherwise the opposite effect was obtained increasing the ionic strength with 
NaCl. Also the protein concentration had a negative effect on the total protein 
stability although this effect was lower compared to the ionic strength. The 
incubation time and the temperature, considered as singular factors, did not 
play a significant effect on the model. Conversely, a significant effect was 
observed when these two factors interacted each other. When there is an 
interaction between two factors, the effect of one depends on the levels of the 
other factor. 
a)                                                                      b) 
 
 
Figure 29: Summary of fit (a) and coefficient plot (b) of the model proposed for the 
stability testing 
 
Figure 30 shows all the interactions of the variables identified in the model. 
In particular, the incubation time and the temperature showed a strong 
interaction, i.e. the two lines intersect each other. Considering the results 
obtained from R.T. samples, increasing the incubation time, the stability of the 
total proteins was reduced but at lower temperature this effect was the opposite. 
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A weak interaction was identified for the ionic strength and pH: as a matter of 
fact, the two lines are not parallel although, in the range of ionic strength used, 
do not intersect. In particular, starting from high or low pH values when NaCl 
concentration was increased the total protein content decreased. The same 
trend was observed for the more evident interaction between protein 
concentration and ionic strength (Figure 30b). 
The contour plot in Figure 30c resumes the results obtained. In all the tests 
performed, the increase of the ionic strength and the decrease of the pH of the 
samples caused the precipitation of the total proteins and this effect was more 
evident when the total protein concentration was higher.  
 
a)                                                                 b) 
c) 
 
Figure 30: Interaction plot for time vs temperature a) and concentration vs ionic 
strength b). c) Contour plot considering the three significant variables (pH, protein 
concentration and NaCl concentration)  
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4.2.3 Chromatographic capture step: HTPD platform development 
(platform n°2) 
As shown in the decision tree reported in Figure 27, the systematic 
approach continues with the introduction of the capture step for the purification 
of the protein of interest. In this step the aim was to identify, through HTPD 
approaches, a set of chromatographic media able to recover the protein of 
interest and to remove part of the contaminants. Due to its high isoelectric point 
the protein could be captured with a CEX at pH below 9.6 or an AEX at pH 
above the pI. Another option was to test resins, such as hydroxyapatite or 
Eshmuno HCX based on a mixed mode interaction. 
These considerations allowed to set-up an HTPD approach matrix as 
described in Materials and Methods in paragraph 3.3.4. The only three 
variables considered in order to evaluate the binding of the protein of interest 
were pH, ionic strength and total protein loading. The results obtained from 
the screening are reported in Table XIX in form of contour plots generated by 
MODDE. All the graph are represented with the pH values on the x axis and 
ionic strength on the y axis and all the contour plots of total protein content 
and POI content refers to a 1:1 ratio of total protein loaded against the volume 
of resins.  
The effect of buffer pH on the cationic resin screening was relevant 
because the protein of interest increased the binding at decreasing pH up to 7, 
due to its high positive charge. SP Sepharose, Nuvia S and Fractogel SO3 
showed the same trend with about a 50% of POI binding at pH 7 without 
addition of NaCl. Increasing the salt concentration and the pH, the yield of the 
POI decreased. Unfortunately, at low pH the Tris buffer could not be used with 
the cationic resins since its charge is mainly positive and caused a “shield 
effect” on the cationic exchangers. This effect could be observed in the total 
protein content contour plots where the maximum total binding obtained was 
about 30% and this value decreased up to 10% reducing pH and ionic strength. 
The low binding of HCPs on these cationic resins could be also related to the 
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negative charge of most of these proteins at neutral and basic pH as described 
in the literature (50-52).  
Using Eshmuno S and the weak cation exchanger CM Sepharose FF, the 
POI binding increased at low pH, as for the resins mentioned before, and at 
high ionic strength. This latter condition for binding was not easy to explain 
but could be probably attributed to a combination of uncontrolled factors such 
as the nature of matrix, the “shield effect” of Tris buffer, the pI of HCPs and 
POI, and the ionic strength. A same puzzling binding behavior of the POI was 
observed on Poros XS where the binding of the POI was achieved increasing 
the pH. In this case, the main confounding effect could be attributed to the 
polymeric matrix. As a matter of fact, the polystyrene divinylbenzene matrix 
of Poros XS is a common matrix used in Reverse Phase Chromatography 
(RPC) in order to bind and separate HCPs from the POI. Hence, in this case 
the “matrix effect” could explain the unconventional binding of the HCPs and 
of the POI.  
A very high degree of binding of the POI was observed in the two mixed 
mode chromatographic media. In HA a quadratic effect was observed in the 
POI binding reaching a maximum and a high purity at low pH and low ionic 
strength. In Eshmuno HCX a high binding of the POI was observed at low pH 
and at all NaCl concentrations of while the HCPs binding increased only with 
the addition of NaCl in the samples. These behaviors could be explained only 
by the presence of a cationic exchanger and a strong hydrophobic group such 
as the phenyl group. In fact, both the exchangers affect the binding of the POI 
because it is very basic and hydrophobic, therefore, it binds these ligands at 
low pH and at high ionic strength. Differently, the HCPs binding was affected 
mainly by the phenyl group of the matrix at high concentration of NaCl. 
Regarding the effects on anionic chromatographic resins, the outcome of 
pH and ionic strength was more or less identical for the three resins (Nuvia Q, 
Poros HQ and Q Sepharose). The binding of both the POI and HCPs increased 
by increasing the pH and reducing the ionic strength. 
 100 
 
In order to test a scale-up of a capture step, an anionic exchanger was 
chosen because the quaternary ammonium group was the only exchanger able 
to bind the POI at high yields and at the best stability condition identified in 
paragraph 4.2.2 (pH 9.5 at low ionic strength). Unfortunately, this condition 
has some disadvantages in terms of binding of contaminants. In fact, HCPs and 
rDNA bind very strong to the resin and they must be removed in the elution 
step. On the other hand, this choice was ambitious because allowed to test the 
capability of the step by step systematic approach to propose a process able to 
obtain a highly pure POI. Perhaps, a chromatographic step, such as a cationic 
interaction on SP Sepharose at pH 7, could allow an almost complete binding 
of the protein of interest with a reduced amount of HCPs and rDNA. However, 
this approach was affected by a high decrease of the POI (due to precipitation 
in the first step of buffer exchange up to pH 7) and by a reduced yield in the 
chromatographic step. 
 
Table XIX: Contour plots of the eleven resins tested for the introduction of the capture 
step 
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4.2.4 Optimization of the elution conditions on the anionic 
exchangers: DoE platform n°3 
The three resins identified as the best option for the capture step were 
tested with a third DoE platform approach in order to identify the main 
variables that could affect the elution of the POI and HCPs. The variables 
considered in this platform were ionic strength, pH and buffer composition 
(100 mM of phosphate or Tris buffer). The approach was based on a full 
factorial interaction model and the shared POI response surface of the three 
resins is represented in Figure 31.  
  
 
Figure 31: Response surface plot of the full factorial model proposed for the set-up of 
the elution conditions in the anionic exchangers 
The protein of interest eluted with the highest yield at 1 M NaCl and at 
pH 6 in 100 mM phosphate buffer. Hence, the increase of ionic strength had a 
positive effect in POI elution as well as the decrease of pH. In particular, this 
effect was coherent with the increase of the positive repulsive charges on the 
protein of interest. This effect is evident at pH 6 and 0 M NaCl where about 
20% of the POI was eluted. The main effect on protein elution was due to 
these two factors only, whereas the phosphate buffer was useful to partially 
change the Tris buffer content and to shift the buffer capacity at acid pH. 
The data obtained from HCPs Log reduction showed how all the 
conditions tested had a very low Log reductions value, therefore, the model 
generated was not valid and predictive. As a matter of fact, all the elution 
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conditions of the platform were too drastic or too weak to separate the HCPs 
from the POI. Hence, it was necessary to perform a gradient elution step to 
identify the best conditions to reduce the contaminants level. 
4.2.5 Scale-up of the anionic capture step 
As mentioned in the previous paragraph, a gradient elution on the three 
columns was necessary in order to find the best elution condition. The binding 
capacities of the three resins were approximately similar, in particular the total 
protein binding capacity at the 5% breakthrough was about 0.75 mg/mL, while 
the POI was about 0.3 mg/mL. Figure 32 reports the three chromatographic 
profiles of Nuvia Q, Poros HQ and Q Sepharose FF performed on a 1 mL resin 
using a linear gradient from 0 to 100 mM phosphate buffer, 1 M NaCl, pH 6. 
The three profiles shared the same shape characterized by three peaks at 
different retention times. In the Nuvia Q purification the fraction A1 to A7 
referred mainly to a mixture of protein and rDNA, while in Poros HQ and Q 
Sepharose they mainly contained proteins since the absorbance at 280 nm was 
about twice higher than at 260 nm. In all the three chromatograms the second 
peak was mainly rDNA because the A260nm/A280nm ratio was about 1.8, while 
the third peak consisted of proteins. 
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Figure 32: Chromatograms of the Nuvia Q, Poros HQ and Q Sepharose FF 
chromatographies performed with 10 CV gradient elution 
 
The plot in Figure 33 reports the results obtained from ELISA test, HCPs and 
total protein content of the fractions collected from the three purifications. The 
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analysis show that the POI eluted in the last peak of the three chromatograms 
(it was approximately collected in fractions B1 to B12) while 80% of HCPs 
were collected up to fraction A12. Moreover, the ELISA test showed that the 
initial protein content of the POI corresponded to about 25% of the total 
protein content. Table XX resumes the Log reductions for rDNA and HCPs, 
and POI yield in the last chromatographic fraction: the POI was fully 
recovered in the last fraction for all the three resins (possessing a quaternary 
ammonium exchanger) allowing a five-fold reduction of HCPs content.  
 
 
 
Figure 33: Results obtained from ELISA test, HCPs and total protein content of the 
fractions collected from the three purifications. The thin lines represent the total 
protein content, the thick lines the POI content, while the bars represent the HCPs 
percentage content 
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Table XX: Summary table of the three anionic exchangers purifications in terms of 
contaminants reduction and overall recovery 
 NQ PQ Q 
 B1-B12 B1-B12 B1-B12 
HCPs Log red 0.69 0.60 0.75 
rDNA Log red 3.50 3.00 2.90 
POI yield (%) 98% 95% 96% 
 
The best Log reduction in terms of rDNA was apparent for Nuvia Q resin, 
with a value of 3.5. This value, together with the best yield obtained, allowed 
the introduction of this resin in the purification process. The purification on 
Nuvia Q was optimized introducing a stepwise elution; in particular, the results 
obtained in the 1 mL-scale allowed to identify the NaCl concentrations 
required for contaminants removal and POI elution. A first elution step was 
assessed at 150 mM (15 mS/cm corresponding to 15% of buffer B) and the 
elution of the POI was performed at 370 mM NaCl (37 mS/cm corresponding 
to 37% of buffer B). At the end of the chromatographic run the resin was 
regenerated with 100 mM phosphate buffer, 1 M NaCl, pH 6. Figure 34 shows 
the scale-up performed on a 5 mL resin. All the results obtained in the small 
scale were fully reproducible on the 5 mL-column stepwise elution. 
 
Figure 34: Stepwise elution on Nuvia Q resin during the purification of the 13.6 kDa 
protein 
-5
15
35
55
75
95
-5
15
35
55
75
95
115
0 20 40 60 80 100
m
S
/c
m
m
A
U
mL
Abs 280 nm Abs 260 nm Cond mS/cm Conc % B
 107 
 
4.2.6 Introduction of a polishing/intermediate step for the 
purification of the 13 kDa protein 
The same approach proposed for the determination of elution conditions 
on the anionic resins in capture step was performed in order to optimize the 
elution on HA. As described in paragraph 4.2.3, this resin showed a high 
binding capacity of the POI in the 7 to 8 pH range, hence, a DoE was performed 
to set up the elution step. The platform was set up as described in paragraph 
3.3.7 using as starting sample the fraction eluted from Nuvia Q containing the 
POI. Unfortunately, all the conditions tested did not allow the elution of the 
POI; as a matter of fact, the POI was eluted only using a harsh regeneration 
step with NaOH 1 M. Due to the too strong binding of the POI, the HA was 
eliminated from the process development.  
The CIM multus DEAE monolithic column, a weak anion exchanger with 
similar binding characteristics of strong cation exchanger, was thus 
investigated since many information on interaction between the POI and anion 
exchangers were available from platform n°2. 
The peak eluted from Nuvia Q, containing the 13 kDa protein, was diluted 
twenty-fold with 0.1 M Tris-HCl pH 10.5 and loaded on the column. The same 
gradient elution described in paragraph 3.3.6 was performed. Three main 
groups of peaks were identified during the elution by the gradient step: one at 
low conductivity and the others at the end of the gradient when the conductivity 
was very high and the pH was completely shifted from 10.5 to 6 (Figure 35a). 
The SDS-PAGE analysis showed that there were not significant differences in 
the profile of the three fractions (Figure 35b). Also the quantification of the 
HCPs demonstrated that no significant reduction of the protein contaminants 
content was obtained. 
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Figure 35: a) Chromatographic profile of the CIM Multus DEAE column during the 
purification of the 13.6 kDa protein. b) SDS-PAGE of the fractions collected  
 
An additional resin tested for the polishing step was the Phenyl Sepharose 
HP. In order to evaluate the stability of the POI after adding the salts 
responsible of the salting out effect, a DoE approach based on two variables 
was performed. The factors analyzed were the type of salts used (NaCl or 
ammonium sulfate) and their concentrations (range from 0 to 2 M). Figure 36 
show the coefficient plot of the model variables generated by MODDE. 
 
 
 
 
 
 
 
 
Figure 36: Coefficient plot of the stability test performed before the HIC step in order 
to evaluate the effects of NaCl and ammonium sulfate on protein precipitation. “M” 
refers to salts concentrations expressed as molarity 
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The graph shows that an increase in salts concentration affected the 
precipitation of the POI. The POI content was not significatively affected up 
to the concentration of 1 M of the two salts but at 2 M of NaCl the POI content 
dropped to 30%. At 2 M ammonium sulfate the POI content decreased up to 
70%, hence, the NaCl concentration had a stronger negative effect on POI 
stability than ammonium sulfate. A binding test on Phenyl Sepharose HP 
demonstrated that 1 M NaCl did not allow the full binding of the POI, while 
at 1 M ammonium sulfate the binding was complete. Subsequently, three mg 
of total protein were loaded on the HIC column and the proteins were eluted 
with a gradient of 10 CV of WFI (Figure 37a). The fractions collected from 
the elution step were analyzed by SDS-PAGE and WB analysis (Figure 37b) 
and these allowed to set-up the stepwise elution. In particular, the HCPs were 
removed in the first two elution steps at the conductivity of 36 and 20 mS/cm 
without any loss of the POI (Figure 37c fractions 1 and 2). The latter was 
eluted further reducing the conductivity up to 0.2 mS/cm (Figure 37c fraction 
3): this fraction contained the 70% of the POI and the HCPs Log reduction 
was about 1, while the rDNA Log reduction was about 1.5.  
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Figure 37: a) Chromatographic profile of the elution gradient performed on Phenyl 
Sepharose FF. b) SDS-PAGE and WB of the fractions collected during the gradient. 
c) Stepwise elution of the HIC column 
 
In order to further reduce the contaminant content, all the samples obtained 
from the cationic resin screened for the set-up of the capture step were analyzed 
in term of HCPs reduction. Actually SP Sepharose FF resin was chosen for a 
flow through purification step. As a matter of fact, at pH 8 with 150 mM NaCl, 
corresponding to HIC step elution condition, the binding of the POI was about 
50% while the total protein binding was about 75%. Anyway, this step allowed 
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only a very low reduction of HCPs (Log reduction 0.3) and a rDNA reduction 
of 0.1. The SDS-PAGE and WB analysis in Figure 38 show the profile of SP 
FT and eluate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38: SDS-PAGE and WB of the SP Sepharose FT and eluate 
At the end of these three purification steps the sample contained some 
HCPs bands and also additional contaminants at the molecular weight of 35, 
45, 62, 75 kDa and others high MW aggregates. Only with a chromatographic 
step on a RPC source 15 (GE) the protein was completely purified: RPLC 
displacement chromatography for the purification of the POI from its variants 
and E. coli impurities is well documented. The SP FT was loaded on the RPC 
resin (3 mL) equilibrated with 0.1 M CH3COOH and subsequently the elution 
was performed with 30 CV of 0.1 M CH3COOH, 80% acetonitrile. The protein 
was eluted at high degree of homogeneity as confirmed by SDS-PAGE in 
Figure 39 and then was concentrated up to 1 mg/mL in 10 mM acetate buffer, 
75 mM NaCl, pH 5. The yield of the protein of interest, at the end of the 
process, was ~13%, corresponding to approximately 6 mg of purified 
protein/L culture. The HCPs content at the end of the process was about 200 
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ppm and the rDNA content 0.01 ng/mg of POI. Table XXI resumes all the 
purification steps in terms of yield, HCPs and rDNA reduction. 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: SDS-PAGE of the POI at the final stage of purification 
 
Table XXI: Summary of the downstream process development for the 13 kDa protein 
 
 
 
 
 
 
 
 
The DP obtained was tested for bioactivity on the RAT.C6 cell line and 
compared to a commercial preparation of the 13 kDa protein. As shown in 
Figure 40 the purified POI had the same bioactivity profile of the standard one. 
In particular, the two proteins showed two peaks of activity at about 5 and 15 
µg/mL; the protein purified with the proposed process induced 86% of cell 
proliferation compared to the commercial standard, get as 100%. 
 
STEP 
POI 
Yield 
(%) 
HCPs 
Log red 
rDNA 
Log red 
Dialysis/TFF 90% 0 0 
Capture - Nuvia Q 98% 0.7 3.5 
Intermediate 
 Phenyl Sepharose HP 
70% 1.0 1.5 
Polishing 1  
SP Sepharose FF 
65% 0.3 0.1 
Polishing 2- RPC 40% 0.8 0.1 
Dialysis/TFF 80% 0 0 
OVERALL 13% 2.8 5.2 
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Figure 40: Bioactivity tests of the DP compared to the 13 kDa commercial protein used 
as reference. Results represent the average of three independent experiments 
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5.  Discussion 
The biomanufacturing industry is always looking for production 
processes that can be rapidly developed and can produce consistently and 
reproducibly large quantities of pharmaceutical-grade biomolecules at 
moderate costs. In order to fulfill this demand, standards process platforms in 
both upstream cell culture and downstream purification are going to become 
widely established in industry large-scale production of these biomolecules. 
Downstream process of biopharmaceuticals depends on chromatographic 
techniques. In particular, the capture, the intermediate and the polishing steps 
have to ensure high purity degrees, to reduce product- (e.g. protein variants) 
and non-product-related (e.g. host cell proteins, rDNA or endotoxins) 
impurities in order to administrate the purified macromolecules in humans. 
These steps are usually based on ion exchange or hydrophobic interaction 
chromatographic principles. As a general rule, the development of these steps 
requires a “trial and error” sequential design decisions often obtaining results 
in suboptimal performance. Furthermore, large and time-consuming 
experimental sets are often needed to define the process parameters in order to 
obtain satisfactory results.  
For these reasons a detailed process knowledge is becoming an essential 
and integral part of any production step design strategy. The aim is no longer 
to merely find the optimal parameter set, but to define the operating space using 
specific DoE strategies. These tools can generate the required process 
knowledge faster and with less resources, thus increasing the process 
understanding. Two potential solutions have emerged: HTPD and model-based 
design. The introduction of high-throughput methods into process 
development workflows improves efficiency, reduces the development time 
and the sample amount required to set-up the upstream phases and optimizes 
the chromatographic steps or stability studies. 
For instance, the use of high-throughput screening based on 96-wells 
plates and statistical software for the DoE development allowed quick 
selection of most suitable chromatography medium and identification of 
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promising binding and elution conditions for the chromatographic steps. This 
gave a fast and confident start to the purification process development. 
In this PhD project, both HTPD and model-based design approaches were 
combined in order to optimize the purification steps of a downstream process 
or to constitute a key “tool box” of a systematic approach for the downstream 
process development.  
The HTPD and the model design approach were tested in the first part of the 
work where a complete process development for the production of a 340 kDa 
human recombinant protein was proposed. The non-optimized process, 
performed on a 25 L scale, allowed to obtain a product not compliant with EU 
GMP specifications. As a matter of fact, this process was only tested for its 
feasibility in terms of cells cultivation, identification and choice of the 
purification steps, evaluation of single step purification performance and 
investigation of the product formulation. In this work the non-optimized 
process was used as a preliminary scaffold in order to improve the downstream 
process so that it could be adopted in a fully GMP application. At first, the 
centrifugation harvest step was substituted with a scalable depth filtration step 
in order to size a procedure able to process industrial scale volumes of cells 
culture. The second part of the optimization focused on contaminants removal, 
such as HCPs and rDNA, during the purification steps. rDNA is comprised of 
DNA fragments and longer length molecules originating from the host 
organism that may be present in samples from recombinant biological 
processes. This contaminant could be easily reduced by benzonase treatment. 
The Benzonase enzyme is a dimer of identical subunits with molecular weight 
~30 kDa each (with a weight totaling ~60 kDa) that can be used for digest all 
forms of nucleic acid by hydrolyzing them into smaller oligonucleotides of <10 
base pairs in length. Benzonase treatment (9–90 U/mL) is typically carried out 
in batch mode and this enzyme is normally added to a process feed in presence 
of Mg2+ (1-2 mM) in a pH range of 6–10 and at temperatures of 0–42 °C. 
Regulatory authorities do not regulate how much residual endonuclease can be 
in a product. However, biotechnological products manufacturers using it in 
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their processes need data to demonstrate safety/toxicity status and measure 
residual endonuclease that might be present in final preparations for human 
use. For example Merck & Company’s EU patent of VAQTA hepatitis A 
vaccine indicates that residual Benzonase enzyme is lower than 0.0001 ng/dose 
(53). It is important to note that the endonuclease is a process additive and not 
a drug, excipient, or active pharmaceutical ingredient. Benzonase removal 
from a process stream can be accomplished by several downstream unit 
operations, such as an irreversible thermal inactivation (~15 min at a 
temperature >70 °C and 0.02 N NaOH) or the addition of additional 
chromatographic and TFF steps. Such conditions could negatively affect the 
integrity of the drug product or reduce the POI yield. Moreover, removal can 
be demonstrated by showing a lack of residual nuclease activity (which does 
not detect residual nonactive enzyme) and using an ELISA assay for detection 
of total residual Benzonase molecules (both active and nonactive) (54). For 
these reasons, in this PhD work a DNA hydrolysis step was not introduced. 
It is widely reported that arginine facilitates refolding, suppresses 
aggregation, increases reversibility of thermal unfolding, solubilizes insoluble 
pellets and reduces non-specific binding of proteins, in particular aggregates 
(55). In this work a washing step with 50 mM arginine during the capture on 
Q Sepharose FF proved the effectiveness on HCPs reduction of 1.6-fold 
compared to the non-optimized process and the rDNA reduction of 1.7 Log. 
This approach confirmed that arginine weakens HCPs interaction with anionic 
and hydrophobic matrices. 
This process development also introduced a disposable membrane 
chromatographic step stated as a powerful alternative to polishing columns, 
particularly for process-scale recombinant protein purification, because of 
advantages such as high throughput, faster processing time, reduced buffer 
consumption, and elimination of column packing and packing testing 
activities. Membrane adsorbers are not new in the purification background and 
although available in several chemistries, their application has been limited to 
AEX in flow-through or isocratic mode with mostly quaternary amine “Q” 
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chemistry. The results obtained in this work, with the introduction of an AEX 
“flow-through” mode membrane, allowing an additional twofold HCPs 
reduction, agree with the results obtained by Zhou and Tressel (56) and by 
Etzel and Riordan (57) in terms of impurities reduction. The production 
process was finalized with the introduction of a viral inactivation and removal 
step. In particular, using the model based on the assumption of gradual pore 
blockage by particulates in the feed stream as described by Badminton et al. 
(42) was identified the best filter and its size in order to perform the 20 nm 
filtration. 
The HTPD approaches and the DoE model design experiments were 
tested in the optimization of HA and HIC steps of the 340 kDa protein 
production process. These two combined approaches allowed to determine the 
minimal phosphate buffer concentration able to maximize the elution of the 
POI and to reduce the amount of contaminants in HA (3000-fold rDNA content 
reduction and four-fold HCPs reduction). The approaches were equally useful 
in HIC to define arginine and NaCl concentration able to increase POI recovery 
without contaminant content. These two approaches allowed not only to 
identify the best protein elution condition but also to explore and predict the 
entire design space with a statistically significance.  
On the basis of these results, the aim of the second part of this PhD project 
focused on the introduction of a standardized approach to purify recombinant 
proteins. The “tool box” described above, acquired a pivotal role in the 
development of the method: as a matter of fact, each step of the purification 
program was characterized by a predefined set of variables to test with HTPD 
approaches and analyzed by the statistical software. Each recombinant protein 
purification process is unique due to different variables such as the hosts, the 
refolding step, the post-translational modifications and the presence of tags: 
accordingly, it is not possible to define in advance a common design for each 
element of the “tool box” of the approach. However, it is possible to define the 
objective of each step and, on this basis, define if the test could be a screening, 
robustness or an optimization study.  
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The decision tree approach was tested setting up a complete purification 
process of a 13 kDa recombinant protein expressed in E. coli as inclusion 
bodies. After the refolding step, the properties of the POI and of the 
contaminants were collected in order to propose a rational pathway for the 
purification and to interpret the obtained data. A starting platform tested the 
stability of the protein before protein purification: it is crucial to investigate 
the variables that could affect the stability of the protein during the purification 
process in order to avoid conditions that could negatively affect it. In this case 
the objective of the platform was a screening based on a full factorial V+ 
resolution design. In only one day five variables (and their ranges) were 
screened and the obtained results allowed to conclude that the increase of NaCl 
and protein concentration reduced protein stability as well as the interactions 
between NaCl and protein concentration and the incubation time with 
temperature. These results showed that higher concentration of NaCl causes a 
salting out effect and the hydrophobic regions of the POI and HCPs interact 
each other’s creating an insoluble complex. This platform was powerful in 
order to define the operability ranges during all the purification process, that 
were set at basic pH and at low protein concentration. Moreover, the approach 
critically revised previous conclusions about drastic increment of ionic 
strength and pH reduction. 
A complex full factorial design was then proposed for the capture step 
investigation. Eleven resins with different chemical exchangers or matrices 
were screened. This approach had to be interpreted at many levels in term of 
contaminants reduction, of purification approach (“bind and elute” or flow-
through mode) and of confounding effects. In order to explain the interaction 
of the POI with the resins eleven different models were proposed. The platform 
allowed to point out the inadequacy of the POI purification on cationic 
exchangers because of the need to decrease the pH in order to increase the 
positive charge on the protein surface is not compatible with amine based 
buffers. The latter acquire a very pronounced positive charge that causes a 
shield effect on the exchangers reducing the POI interaction. Moreover, this 
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approach allowed to identify how for some resins such as CM sepharose FF, 
Eshmuno S and Poros HS the binding was not easy to explain but could be 
probably attributed to a commingling of uncontrolled factors such as the nature 
of matrix, the “shield effect” of Tris buffer, the pI of HCPs and POI, and the 
ionic strength. The resin chosen was the Nuvia Q resin, based on a quaternary 
ammonium, because the binding was achieved at the best POI stability 
conditions and because allowed to better reduce contaminants during the scale-
up steps. The optimization of the capture step elution was made by a third DoE 
platform where ionic strength, pH and buffer composition were tested. Also in 
this case the model has proved to predict the main effect on protein elution.  
A same approach to test the elution condition was proposed for an 
intermediate step with HA. The results showed the impossibility to employ the 
HA as a mixed mode chromatographic media because the POI binding was too 
high. This effect is due to the strong interaction between phosphate and the 
positive charge of the POI at low pH and high ionic strength. An alternative to 
test, in order to reduce this interaction, might be the addition of calcium 
chloride before loading the POI (and not in elution buffer). In fact, in this latter 
case, the Ca2+ ions did not have any effect in competing with the POI for 
phosphate group binding, while the early addition of the salts it may convert 
the HA resin in a full anionic resin reducing the interaction at low pH. Future 
studies will investigate this effect as the possibility to deeply study different 
mixed mode chromatography such as Eshmuno HCX, due its suppleness and 
its capability in aggregate reduction. 
The intermediate step was committed to Phenyl Sepharose HP where a 
DoE approach as in the first platform was tested to investigate the effect of 
ammonium sulfate and NaCl in the salting out step before the loading on the 
HIC column. Differently from NaCl, ammonium and sulfate both belong to 
the Hofmeister series and are among the most stabilizing ions. For the POI, it 
was also confirmed the effect of ammonium sulfate, which is commonly used 
to precipitate and store proteins for long standing or preserves the native state 
of proteins for purification steps. 
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Although a final polishing step was not able to obtain the desired purity, 
an iterative approach was proposed in order to reduce HCPs and rDNA. The 
information obtained from the capture step platform, where the study was 
performed in order to propose a “bind and elute” mode, were used to identify 
SP Sepharose FF as resin to be used in a flow-through mode. This approach 
showed that the HTPD-model based approach generate a massive amount of 
information that the experimenter can use not only in the steps where these 
data were obtained but also in others because this approach has a predictive 
behavior. 
The process described in the second part of the work allowed to obtain a 
pure and active preparation of the 13 kDa protein containing an amount of 200 
ppm of HCPs and 0.01 ng/mg of rDNA. 
The decision tree presented in this PhD work was a combination of in silico 
and in vitro analyses proposed to develop a strategy for downstream bio-
processing biomolecules. Significant DoE investments in experimental and 
computing facilities have resulted in scientific data being generated in 
unprecedented volumes and velocities. Machine learning techniques have 
proven to be invaluable in the commercial world therefore these approaches 
could be implemented to extract insights from current and future scientific 
datasets, thereby enhancing scientific productivity and providing maximal 
science impact from existing DOE investments. 
 The DoE is gaining wider acceptance as another valuable tool for process 
optimization in the pharmaceutical industry. Using this kind of approach the 
experimental work and the analyses are reproducible and the time required for 
process development may be cut in half or decreased even further (58). The 
starting point of the approach was to understand the physico-chemical 
properties of potential contaminants and by-products of the host expression 
system. The knowledge obtained can direct the engineering of an effective and 
efficient downstream bio-processing operation. Care must be taken in choosing 
the appropriate equipment and technologies to ensure product purity, integrity 
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and safety, while creating an economic and efficient process based on sound 
manufacturing science. 
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